Drug Database · Clinicians

Levetiracetam

Brands (146) Focale, Keppra, Leveget…Show all
Focale · Keppra · Leveget · Kepdin · Dretacen · Leveleptic · Leveram · Levetrex · Levetroy · Levtrawell · Zolevi · Ceaser 1000 · Czure · Exppra 500 · Ivetra IV · Julitam I.V. · Leavur · Lepixa · Letram · Levacetam · Levexam · Levit · Levit IV · Levixam · Logufen · Neurolev · Seiz 500 · Akucetam-1000 · Akucetam-500 · Alevra · Asynlev · Ceaser 500 · Cetafer · Cetanerv · Devetam · Devetam 1000 · Dretazure · Epcetam · Epilept · Epiloz · Epivra · Epsytam · Eterlox · Etiraxin · Flexivate · Gentracet · Gocetam · Golevet IV · Golyptin · Ivetra 1000 · Ivetra 250 · IVETRA 500 · Ivetra-100 · Julitam · Julitam 1000 · Julitam 250 · Julitam 500 · Julitam 750 · Juvicet · Kepdin Syrup · Kepreptol · Klevra · Leciteram 1000 · Leciteram 250 · Leciteram 500 · Lecitram · Lentira · Lepiva 250 · Lepiva-500 · Lepixa 1000 · Lepixa 500 · Lepmed · Lepstop · Leptam · Leptam Tab · Leteram-250 · Leteram-500 · Levcetam · Levecare · Levecetam · Levelife · Levellen-PE500 · Levensa IV · Levephase · Leveragen · LEVERAP · Levero · Levesaph · Levestal · Levestal-500 · Levesync · Levetigrand 250 · Levetigrand 500 · Levetirasaph-Alt · Levetra · Levetramed - 1000 · Levetramed - 500 · Levetricare · Leviacet 250 · Levidex · Levifar · Levinov · Levipam · Levipil · Levipil 500 · Levipil 750 · Levipil XR 1000 · Levipil XR 1500 · Levipra 250 · Levipra 500 · Levirtigen · Levitam 1000 · Levitam 500 · Levitar · Levitar-S · Levitra · Levizam 500 · Levsezur · Levtrazem · Levtraztam · Lezure · Lumark-250 · Lumark-500 · Malcetam · Masolev · MASOSAVE · Myolev · Novacetam · Racet-S · Rancetam-1000 · Raxetacs · Reflate 500 · Renaior · Salvetam · Seiletam · SEIZ OS · Sezuvin · Tiracezan · Troycetam · Vexlev 100 · Vexlev 250 · Vexlev 500 · Vexlev IV · Xolcetam · Xolvecetam · Zeiskon

Antiepileptic agent; Antiepilepticon; and others PH FDA category

Dose by CrCl; supplement after HDRx · Prescription drug214 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 3ca9df05-a506-4ec8-a4fe-320f1219ab21, version date January 28, 2026 (Keppra · UCB, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older
  • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy
  • Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) KEPPRA is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3) 1.1 Partial-Onset Seizures KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy KEPPRA is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures KEPPRA is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.

Contraindications

  • Hypersensitivity to levetiracetam
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS KEPPRA is contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.4)]. Known hypersensitivity to levetiracetam; angioedema and anaphylaxis have occurred (4, 5.4)

Dosing: Adult

  • Partial-onset seizures (adults, 16 years and older): 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to 1,500 mg twice daily
  • Myoclonic and primary generalized tonic-clonic seizures (adults): Same titration to 1,500 mg twice daily
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • Use the oral solution for pediatric patients with body weight ≤ 20 kg (2.1)
  • For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) (2.1)
  • Partial-Onset Seizures (monotherapy or adjunctive therapy) 1 Month to < 6 Months: 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily (2.2)
  • 6 Months to < 4 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily (2.2)
  • 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.2)
  • Adults 16 Years and Older: 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily (2.2)
  • Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily (2.3)
  • Primary Generalized Tonic-Clonic Seizures 6 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.4)
  • Adults 16 Years and Older: 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily (2.4)
  • …
2.1 Important Administration Instructions

2.1 Important Administration Instructions KEPPRA is given orally with or without food. The KEPPRA dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function. Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon). KEPPRA tablets should be swallowed whole. KEPPRA tablets should not be chewed or crushed.

2.2 Dosing for Partial-Onset Seizures

2.2 Dosing for Partial-Onset Seizures The recommended dosing for monotherapy and adjunctive therapy is the same; as outlined below. Adults 16 Years of Age and Older Initiate treatment with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg.

There is no evidence that doses greater than 3000 mg/day confer additional benefit. Pediatric Patients 1 Month to < 6 Months Initiate treatment with a daily dose of 14 mg/kg in 2 divided doses (7 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 14 mg/kg to the recommended daily dose of 42 mg/kg (21 mg/kg twice daily).

In the clinical trial, the mean daily dose was 35 mg/kg in this age group. 6 Months to < 4 Years: Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose in 2 weeks by an increment of 20 mg/kg to the recommended daily dose of 50 mg/kg (25 mg/kg twice daily). If a patient cannot tolerate a daily dose of 50 mg/kg, the daily dose may be reduced.

In the clinical trial, the mean daily dose was 47 mg/kg in this age group. 4 Years to < 16 Years Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced.

In the clinical trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day. For KEPPRA tablet dosing in pediatric patients weighing 20 to 40 kg, initiate treatment with a daily dose of 500 mg given as twice daily dosing (250 mg twice daily). Increase the daily dose every 2 weeks by increments of 500 mg to a maximum recommended daily dose of 1500 mg (750 mg twice daily).

For KEPPRA tablet dosing in pediatric patients weighing more than 40 kg, initiate treatment with a daily dose of 1000 mg/day given as twice daily dosing (500 mg twice daily). Increase the daily dose every 2 weeks by increments of 1000 mg/day to a maximum recommended daily dose of 3000 mg (1500 mg twice daily). KEPPRA Oral Solution Weight-Based Dosing Calculation For Pediatric Patients The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients: Total daily dose (mL/day) = Daily dose (mg/kg/day) × patient weight (kg) ------------------------------------------------ 100 mg/mL

2.3 Dosing for Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile

2.3 Dosing for Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile Myoclonic Epilepsy Initiate treatment with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase the dosage by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

2.4 Dosing for Primary Generalized Tonic-Clonic Seizures Adults 16 Years of Age and Older

2.4 Dosing for Primary Generalized Tonic-Clonic Seizures Adults 16 Years of Age and Older Initiate treatment with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase dosage by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

Pediatric Patients 6 to <16 Years of Age Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied.

Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)]. Only whole tablets should be administered.

2.5 Dosage Adjustments in Adult Patients with Renal Impairment

2.5 Dosage Adjustments in Adult Patients with Renal Impairment KEPPRA dosing must be individualized according to the patient's renal function status. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated.

To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula: CLcr= [140-age (years)] × weight (kg) ---------------------------------------- 72 × serum creatinine (mg/dL) (× 0.85 for female patients) Then CLcr is adjusted for body surface area (BSA) as follows: CLcr (mL/min/1.73 m² )= CLcr (mL/min) ------------------------------ BSA subject (m 2) × 1.73 Table 1: Dosing Adjustment Regimen for Adult Patients with Renal Impairment Group Creatinine Clearance (mL/min/1.73 m²) Dosage (mg) Frequency Normal > 80 500 to 1,500 Every 12 hours Mild 50 – 80 500 to 1,000 Every 12 hours Moderate 30 – 50 250 to 750 Every 12 hours Severe < 30 250 to 500 Every 12 hours ESRD patients using dialysis ---- 500 to 1,000 Following dialysis, a 250 to 500 mg supplemental dose is recommended. Every 24 hours

2.6 Discontinuation

2.6 Discontinuation of KEPPRA Avoid abrupt withdrawal from KEPPRA in order to reduce the risk of increased seizure frequency and status epilepticus [see Warnings and Precautions (5.8)].

Dosing: Altered kidney function

Levetiracetam is cleared mainly by the kidneys (66% unchanged). The US label reduces the dose by creatinine clearance adjusted for body surface area and, for dialysis patients, gives 500 to 1,000 mg every 24 hours plus a 250 to 500 mg supplement after each hemodialysis, which removes about 50% in 4 hours.

Kidney function measure: Label uses Cockcroft-Gault CrCl adjusted to body surface area (mL/min/1.73 m2): >80, 50–80, 30–50, <30, and ESRD on dialysis. Site bands keep this measure; label cut-offs inside a band are stated.

Show full dosing details
CrCl ≥60 mL/min
CrCl >80: 500 to 1,500 mg every 12 hours. CrCl 50–80: 500 to 1,000 mg every 12 hours (label Table 1).
CrCl 30–59 mL/min
CrCl 50–80: 500 to 1,000 mg every 12 hours. CrCl 30–50: 250 to 750 mg every 12 hours (label Table 1).
CrCl 15–29 mL/min
CrCl <30: 250 to 500 mg every 12 hours (label Table 1).
CrCl <15 mL/min (not on dialysis)
CrCl <30: 250 to 500 mg every 12 hours (label Table 1).
Hemodialysis (intermittent)
ESRD on dialysis: 500 to 1,000 mg every 24 hours, plus a 250 to 500 mg supplemental dose after each dialysis (label Table 1). About 50% removed in a 4-hour session.
Peritoneal dialysis
The label's ESRD-on-dialysis row (500 to 1,000 mg every 24 hours) does not separate PD from HD; the post-dialysis supplement is for hemodialysis. Applying the 24-hour dose to PD without a supplement is clinical extrapolation; specialist input.
CRRT
No data in label. Removed by dialysis, so CRRT likely clears it; specialist input and seizure monitoring.
  • Dialyzable? Yes: about 50% of the body pool removed in a standard 4-hour hemodialysis (label 10.3, 12.3).
  • Monitoring Kidney function (CrCl) to set the dose. Seizure control. Behavioral changes, mood, suicidal thinking; somnolence and coordination problems. Avoid abrupt withdrawal.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Weight-based dose by age (label).
eGFR 30–59
The label's kidney dosing table is for adults only; no pediatric kidney dose is given. Clearance falls with CrCl, so reduce by clinical judgment with specialist input.
eGFR 15–29
No pediatric kidney dose in label. Specialist input.
eGFR <15 (not on dialysis)
No pediatric kidney dose in label. Specialist input.
Hemodialysis (intermittent)
No pediatric dialysis dose in label; dialyzable (supplement after HD likely needed). Specialist input.
Peritoneal dialysis
No data. Specialist input.
CRRT
No data. Specialist input.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.5 Dosage Adjustments in Adult Patients with Renal Impairment KEPPRA dosing must be individualized according to the patient's renal function status. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated.

To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula: CLcr= [140-age (years)] × weight (kg) ---------------------------------------- 72 × serum creatinine (mg/dL) (× 0.85 for female patients) Then CLcr is adjusted for body surface area (BSA) as follows: CLcr (mL/min/1.73 m² )= CLcr (mL/min) ------------------------------ BSA subject (m 2) × 1.73 Table 1: Dosing Adjustment Regimen for Adult Patients with Renal Impairment Group Creatinine Clearance (mL/min/1.73 m²) Dosage (mg) Frequency Normal > 80 500 to 1,500 Every 12 hours Mild 50 – 80 500 to 1,000 Every 12 hours Moderate 30 – 50 250 to 750 Every 12 hours Severe < 30 250 to 500 Every 12 hours ESRD patients using dialysis ---- 500 to 1,000 Following dialysis, a 250 to 500 mg supplemental dose is recommended. Every 24 hours

8.6 Renal Impairment Clearance of levetiracetam is decreased in patients with renal impairment and is correlated with creatinine clearance [see Clinical Pharmacology (12.3)]. Dose adjustment is recommended for patients with impaired renal function and supplemental doses should be given to patients after dialysis [see Dosage and Administration (2.5)].

Renal Impairment The disposition of levetiracetam was studied in adult subjects with varying degrees of renal function. Total body clearance of levetiracetam is reduced in patients with impaired renal function by 40% in the mild group (CLcr = 50-80 mL/min), 50% in the moderate group (CLcr = 30-50 mL/min) and 60% in the severe renal impairment group (CLcr <30 mL/min).

Clearance of levetiracetam is correlated with creatinine clearance. In anuric (end stage renal disease) patients, the total body clearance decreased 70% compared to normal subjects (CLcr >80 mL/min). Approximately 50% of the pool of levetiracetam in the body is removed during a standard 4- hour hemodialysis procedure [see Dosage and Administration (2.5)].

Dosing: Pediatric

Approved ages
Partial-onset seizures from 1 month; myoclonic seizures 12 years and older; primary generalized tonic-clonic seizures 6 years and older (label).
Usual dose
Partial-onset: 1 to <6 months, 7 mg/kg twice daily up to 21 mg/kg twice daily; 6 months to <4 years, 10 up to 25 mg/kg twice daily; 4 to <16 years, 10 up to 30 mg/kg twice daily (label 2.2).
Maximum dose
30 mg/kg twice daily (4 to <16 years); do not exceed adult maximum 3,000 mg/day.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of KEPPRA for the treatment of partial-onset seizures in patients 1 month to 16 years of age have been established [see Clinical Pharmacology (12.3) and Clinical Studies (14.1)]. The dosing recommendation in these pediatric patients varies according to age group and is weight-based [see Dosage and Administration (2.2)].

The safety and effectiveness of KEPPRA as adjunctive therapy for the treatment of myoclonic seizures in adolescents 12 years of age and older with juvenile myoclonic epilepsy have been established [see Clinical Studies (14.2)]. The safety and effectiveness of KEPPRA as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in pediatric patients 6 years of age and older with idiopathic generalized epilepsy have been established [see Clinical Studies (14.3)].

Safety and effectiveness for the treatment of partial-onset seizures in pediatric patients below the age of 1 month; adjunctive therapy for the treatment of myoclonic seizures in pediatric patients below the age of 12 years; and adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in pediatric patients below the age of 6 years have not been established. A 3-month, randomized, double-blind, placebo-controlled study was performed to assess the neurocognitive and behavioral effects of KEPPRA as adjunctive therapy in 98 (KEPPRA N=64, placebo N=34) pediatric patients, ages 4 to 16 years old, with partial seizures that were inadequately controlled.

The target dose was 60 mg/kg/day. Neurocognitive effects were measured by the Leiter-R Attention and Memory (AM) Battery, which measures various aspects of a child's memory and attention. Although no substantive differences were observed between the placebo and drug treated groups in the median change from baseline in this battery, the study was not adequate to assess formal statistical non-inferiority of the drug and placebo.

The Achenbach Child Behavior Checklist (CBCL/6-18), a standardized validated tool used to assess a child's competencies and behavioral/emotional problems, was also assessed in this study. An analysis of the CBCL/6-18 indicated on average a worsening in KEPPRA-treated patients in aggressive behavior, one of the eight syndrome scores [see Warnings and Precautions (5.1)].

Juvenile Animal Toxicity Data Studies of levetiracetam in juvenile rats (dosed on postnatal days 4 through 52) and dogs (dosed from postnatal weeks 3 through 7) at doses of up to 1800 mg/kg/day (approximately 7 and 24 times, respectively, the maximum recommended pediatric dose of 60 mg/kg/day on a mg/m 2 basis) did not demonstrate adverse effects on postnatal development.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use There were 347 subjects in clinical studies of KEPPRA that were 65 and over. No overall differences in safety were observed between these subjects and younger subjects. There were insufficient numbers of elderly subjects in controlled trials of epilepsy to adequately assess the effectiveness of KEPPRA in these patients.

Levetiracetam is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Clinical Pharmacology (12.3)].

Administration

2.1 Important Administration Instructions KEPPRA is given orally with or without food. The KEPPRA dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function. Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg. When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon). KEPPRA tablets should be swallowed whole. KEPPRA tablets should not be chewed or crushed.

US FDA label

Dosage forms

Philippines

  • Film-coated tablet: 1 g, 250 mg, 500 mg, 750 mg, 1000 mg
  • Oral solution: 100 mg/mL
  • ) solution for injection: 100 mg/mL (500 mg/5 mL, 100 mg/mL (500 mg/mL
  • ) concentrated solution for injection: 100 mg/mL (500 mg/5 mL
  • Tablet: 250 mg, 500 mg
  • Concentrate solution for injection: 100 mg/mL
  • Concentrate for solution for iv infusion: 100 mg/mL, 500 mg/5 mL
  • Solution for injection: 100 mg/mL
  • Syrup: 100 mg/mL
  • ) concentrate for solution for iv infusion: 100 mg/mL (500 mg/5 mL

and 10 more forms; see the products table.

Registered products in the Philippines

214 products registered with the Food and Drug Administration (FDA) Philippines list Levetiracetam as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products214
Philippine FDA-registered products for Levetiracetam
Package insert
Akucetam-1000Levetiracetam
1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4584
Aug 5, 2028
Akucetam-500Levetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4583
Aug 5, 2028
AlevraLevetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Bafna Pharmaceuticals LimitedIndia
Synmosa Biopharma Philippines, Inc.Importer: Medethix, Inc.
DRP-13283-02
Feb 2, 2028
AsynlevLevetiracetam
500 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 30's)
Rx
Bafna Pharmaceuticals LimitedIndia
Synmosa Biopharma Philippines Inc.Importer: MedEthix, Inc.
DRP-13281-01
Feb 2, 2028
Ceaser 1000Levetiracetam
1 g Film-Coated TabletOpaque White Alu- PVC/PE/PVDC Blister Pack x 15's (Box of 60's)
Rx
Pharmathen SAGreece
Saifen Drugs Philippines, Inc.
DR-XY49155
Aug 1, 2029
Ceaser 1000Levetiracetam
1 g Film-Coated TabletOpaque White Alu-PVC/ PE/ PVDC Blister Pack x 15's (Box of 60’s)
Rx
Pharmathen SAGreece
Saifen Drugs Philippines, Inc.
DRP-15815
Aug 1, 2029
Ceaser 500Levetiracetam
500 mg Film-Coated TabletPVC/PE/PVDC Blister Pack x 10’s (Box of 60’s)
Rx
PHARMATHEN S.A.Greece
Saifen Drugs Philippines Inc.
DR-XY49792
Sep 16, 2031
CetaferLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Ferma Drug Enterprises
DRP-16434-04
Mar 11, 2027
CetanervLevetiracetam
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's(Box of 30's)
Rx
Zhejiang Jingxin Pharmaceutical Co. Ltd.China
Hexagon Pharmaceuticals
DRP-16334
Feb 7, 2030
CzureLevetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-13518-01
Mar 3, 2028
CzureLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-13517-01
Mar 3, 2028
DevetamLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Diafarm Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4583-08
Aug 5, 2028
Devetam 1000Levetiracetam
1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Diafarm Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4584-02
Aug 5, 2028
DretacenLevetiracetam
1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's)
Rx
Lek Pharmaceuticals D.D.Slovenia
Sandoz Philippines Corporation
DRP-5280
Apr 23, 2029
DretacenLevetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's)
Rx
Lek Pharmaceuticlas D.D.Slovenia
Sandoz Philippines Corporation
DRP-7486
Feb 13, 2029
DretacenLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's)
Rx
Lek Pharmaceuticals D.D.Slovenia
Sandoz Philippines Corporation
DRP-7484
Feb 13, 2029
DretazureLevetiracetam
100 mg/mL SyrupAmber colored PET Bottle x 100 mL (Box of 1’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant II)India
Diafarm Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4984-02
Dec 11, 2028
EpcetamLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-13517-05
Mar 3, 2028
EpileptLevetiracetam
500mg/5mL Concentrate For Solution For Infusion5 mL USP Type I Flint vial sealed with 20 mm grey bromo butyl rubber stopper and aluminum with blue flip - off seal (Box of 10's)
Rx
Maiva Pharma Pvt. Ltd.India
Medethix, Inc.Trader: Adi Solutions Pty. Ltd.
DR-XY47953
Apr 21, 2027
EpilozLevetiracetam
100mg/mL (500mg/5mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5mL (Box of 10's)
Rx
Aroma Ilac San. LTD. STITurkey
Central West Medicale Inc.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac, San. Ve Tic. A.S.
DRP-10900-05
Dec 14, 2026
EpivraLevetiracetam
100 mg/mL (500 mg/5 mL) Concentrate For Solution For IV InfusionUSP Type I clear glass vial x 5 mL (net content) with grey bromobutyl rubber stopper, aluminum seal, and blue flip-off cap (Box of 10's & 25's)
Rx
Kwality Pharmaceuticals Ltd.India
Pharma-Surrey International, Inc.
DRP-17876
Mar 30, 2031
EpsytamLevetiracetam
500mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 60's) Box of 60's
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Aldril Pharmaceuticals, Inc.
DRP-15237
Dec 19, 2028
EterloxLevetiracetam
500 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 20's)
Rx
PT. Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY49619
Feb 3, 2031
EtiraxinLevetiracetam
100 mg / mL Oral SolutionBoston Round Amber Glass Bottle x 300 mL (Box of 1's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-16898-01
Aug 11, 2030
Exppra 500Levetiracetam
500 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Exemed PharmaceuticalsIndia
Saifen Drugs Philippines, Inc.
DR-XY49156
Aug 1, 2029
Exppra 500Levetiracetam
500 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10’s (Box of 30’s)
Rx
Exemed PharmaceuticalsIndia
Saifen Drugs Philippines, Inc.
DRP-15773
Aug 1, 2029
FlexivateLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4583-11
Aug 5, 2028
FocaleLevetiracetam
1 g Film-coated TabletAlu/Clear PVC/PVdC/PVC blister pack x 10's (Box of 30's)
Rx
Atlantic Pharma - Producoes Farmaceuticas, S.A.Portugal
UNILAB, Inc.
DR-XY46340
May 11, 2028
FocaleLevetiracetam
100mg/mL Oral Solution200 mL Type III amber glass bottle with child-resistant plastic cap x 150 mL + 3 mL-capacity PP oral dosing syringe (Box of 1's)
Rx
Hetero Labs Limited (Unit III)India
Unilab, Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-9033-06
Aug 20, 2031
FocaleLevetiracetam
250 mg Film-coated TabletAlu/Clear PVC/PVdC/PVC blister pack x 10's (Box of 30's)
Rx
Atlantic Pharma - Producoes Farmaceuticas, S.A.Portugal
UNILAB, Inc.
DR-XY46338
May 11, 2028
FocaleLevetiracetam
500 mg / 5 mL Concentrate for Solution for IV InfusionType I Clear Glass Vial with bromobutyl rubber stopper and aluminum flip-off cap x 5 mL (Box of 10's)
Rx
Pharmathen SAGreece
UNILAB, Inc.
DRP-12365
Jul 26, 2027
FocaleLevetiracetam
500 mg Film-coated TabletAlu/Clear PVC/PVdC/PVC Blister Pack x 10's (Box of 30's
Rx
Atlantic Pharma - Producoes Farmaceuticas, S.A.Portugal
UNILAB, Inc.
DR-XY46339
May 11, 2028
GentracetLevetiracetam
100 mg /mL (500 mg/ 5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5 mL (Box of 2's, 4's, and 10's)
Rx
Aroma İlaç San. Ltd. ŞtiTurkey
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical, Inc.Trader: Polifarma İlaç San. Ve Tic. A.S.
DRP-10900-06
Dec 14, 2026
GocetamLevetiracetam
500mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Acme Formulation Pvt. Ltd.India
Applied Pharmaceutical Distribution IncImporter: Medinova Pharmaceutical Inc.
DRP-10808-01
Nov 25, 2026
Golevet IVLevetiracetam
100mg/mL (500mg/5mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glasss Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5mL (Box of 10's)
Rx
Aroma Ilac San. Ltd. StiTurkey
Go Healthcare Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac, San. Ve Tic. A.S.
DRP-10900-02
Dec 14, 2026
GolyptinLevetiracetam
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's; Box of 60's)
Rx
Zhejiang Jingxin Pharmaceutical Co. Ltd.China
Applied Pharmaceutical Distribution IncImporter: Medinova Pharmaceutical Inc.
DRP-13585-03
Mar 14, 2028
Ivetra 1000Levetiracetam
1 g Film-Coated TabletAlu/PVC/PVDC Blister Pack X 10's (Box of 60's)
Rx
TORRENT PHARMACEUTICALS, LTD.India
TORRENT PHARMA PHILIPPINES, INC.
DRP-2410
Oct 14, 2029
Ivetra 250Levetiracetam
250 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 60's)
Rx
Torrent Pharmaceuticals Ltd.India
Importer: Torrent Pharma Philippines Inc.
DRP-2408
Jan 22, 2030
IVETRA 500Levetiracetam
500 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 60's)
Rx
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DRP-2409
Oct 15, 2029
Ivetra IVLevetiracetam
100 mg/ mL (500 mg/5mL) Solution for Injection (IV)USP Type I Glass Vial Sealed with 20 mm Grey Rubber Stopper and Blue Aluminum Flip-off Seal x 5 mL (Box of 1's)
Rx
Aspiro Pharma LimitedIndia
Torrent Pharma Philippines Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-9232-01
Jul 6, 2031
Ivetra IVLevetiracetam
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Borosilicate Glass Vial with Gray Rubber Stopper and Aluminum Plastic Overseal Cap x 10 mL (Box of 1’s)
Rx
Hainan Poly Pharm. Co., Ltd.China
Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation
DRP-11179-02
Feb 10, 2027
Ivetra-100Levetiracetam
100 mg /mL Oral Solution200 mL Type III amber glass bottle with child-resistant plastic cap x 150 mL + 3 mL-capacity pp oral dosing syringe (Box of 1's)
Rx
Hetero Labs Limited (Unit III)India
Torrent Pharma Philippines, Inc.Importer: Camber Pharmaceuticals, inc.
DRP-9033-01
Jun 9, 2031
JulitamLevetiracetam
100 mg/mL Oral Solution200 mL Type III amber glass bottle with child–resistant plastic cap x 150 mL + 3 mL - capacity PP oral dosing syringe (Box of 1’s)
Rx
Hetero Labs LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-9033-05
Jul 15, 2031
Julitam 1000Levetiracetam
1 g Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's)
Rx
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines, Inc.
DRP-7351
Dec 18, 2028
Julitam 250Levetiracetam
250 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's); Alu/PVDC Blister Pack x 10's As physician's sample: Box of 10's
Rx
Cadila Healthcare Ltd.India
Zydus Healthcare Philippines, Inc.
DRP-7576
Dec 18, 2028
Julitam 500Levetiracetam
500 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's Box of 100's
Rx
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines, Inc.
DRP-7322
Dec 18, 2028
Julitam 750Levetiracetam
750 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's)
Rx
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines, Inc.
DRP-7350
Dec 18, 2028
Julitam I.V.Levetiracetam
100 mg/mL Concentrate Solution for Injection (IV Infusion)Type I Clear Colorless Flint Ampoule x 5 mL in Plastic Tray (Box of 1’s)
Rx
Troikaa Pharmaceuticals LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Troikaa Pharmaceuticals Philippines, Inc.
DRP-15623-01
May 21, 2030
Julitam I.V.Levetiracetam
100mg/mL (500mg/5mL)Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5mL (Box of 10's)
Rx
Aroma Ilac San. Ltd. StiTurkey
Zydus Healthcare Philippines Inc.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac San. Ve Tic. A.S.
DRP-10900-01
Dec 14, 2026
JuvicetLevetiracetam
100 mg/mL (500 mg/5 mL) Concentrate Solution for Injection (1.V. Infusion)Clear USP Type I glass vial x 5 mL closed with a gray bromobutyl rubber stopper and blue flip-off seal (Box of 1’s)
Rx
Ciron Drugs & Pharmaceuticals Pvt. LimitedIndia
Phil Pharmawealth, Inc.Trader: Oboi Laboratories
DR-XY49533
Oct 2, 2030
KepdinLevetiracetam
100 mg/mL Oral Solution300 mL Wide Mouth Boston Round Amber Bottle (Box of l’s)
Rx
Lifesquare Laboratories Inc.Philippines
Trader: Medchoice CNS Pharma Corporation
DRP-12346
Jul 21, 2027
KepdinLevetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Medchoice CNS Pharma CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4585-01
Aug 5, 2028
KepdinLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Medchoice CNS Pharma CorporationImporter: Pharmakon Biotec Inc.
DRP-13517-3
Mar 3, 2028
KepdinLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Medchoice CNS Pharma CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4583-01
Aug 5, 2028
Kepdin SyrupLevetiracetam
100 mg/mL SyrupAmber Colored PET Bottle x 100 mL (Box of 1’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant II)India
Medchoice CNS Pharma CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Limited
DRP-4984
Dec 11, 2028
KeppraLevetiracetam
1 g Film-Coated TabletBlister Pack of 10's (Box of 60's)
Rx
UCB Pharma SABelgium
Importer: GlaxoSmithKline Philippines Inc.
DR-XY29122
Mar 4, 2028
KeppraLevetiracetam
100 mg/mL Oral SolutionUSP Type III Amber Glass Bottle with white polypropylene child-resistant closure system x 300 mL (Box of 1's)
Rx
Next Pharma SAS - LimayFrance
Importer: GlaxoSmithKline Philippines Inc.
DR-XY34709
Jul 10, 2028
KeppraLevetiracetam
250 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 60's)
Rx
UCB Pharma SABelgium
Importer: GlaxoSmithKline Philippines Inc.
DR-XY29934
Nov 20, 2027
KeppraLevetiracetam
500 mg Film-Coated TabletBlister Pack of 10's (Box of 60's)
Rx
UCB Pharma SABelgium
Importer: GlaxoSmithKline Philippines, Inc.
DR-XY29131
Mar 4, 2028
KeppraLevetiracetam
500 mg/5 mL Concentrate for Solution for IV InfusionType I clear and colorless glass vial x 5 mL with orange flip-off seal in a plastic tray x 5's (Box of 10's)
Rx
Patheon Italia S.p.A.Italy
Importer: GlaxoSmithKline Philippines, Inc.
DR-XY36632
Sep 10, 2029
KepreptolLevetiracetam
500 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 60's)
Rx
WhanIn Pharm. Co., Ltd.Republic of Korea
Bell-Kenz Pharma Inc.Importer: JLT Pharma Inc.
DRP-8354
Sep 3, 2029
KlevraLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 90's)
Rx
PharmEvo (Pvt.) Ltd.Pakistan
Accesspoint International Trading Inc.
DRP-4816
Oct 14, 2028
LeavurLevetiracetam
1 g Film-coated TabletPVC/PE/PVDC/Alu Triple Laminated Clear Blister Foil x 10's (Box of 30's)
Rx
Aurobindo Pharma Limited, Formulation Unit - XVIndia
AAA Pharma, Inc.
DRP-16780
Jul 10, 2030
LeavurLevetiracetam
500 mg Film Coated TabletPVC/PE/PVDC/Alu Triple Laminated Clear Blister Foil x 10's (Box of 30's)
Rx
Aurobindo Pharma Limited, Formulation Unit - XVIndia
AAA Pharma, Inc.
DRP-16824
Jul 21, 2030
Leciteram 1000Levetiracetam
1g Film-Coated TabletAlu-Clear PVC/PVDC Blister Pack x 10's (Box of 60's and 100's)
Rx
SunGlow Lifescience Private Limited.India
Despina Pharma Inc.
DRP-16132
Nov 7, 2029
Leciteram 250Levetiracetam
250 mg Film-Coated TabletAlu-Clear PVC/PVDC Blister Pack x 10's (Box of 60's and 100's)
Rx
SunGlow Lifesciences Private LimitedIndia
Despina Pharma Inc.
DRP-16134
Nov 7, 2029
Leciteram 500Levetiracetam
500 mg Film-Coated TabletAlu-Clear PVC/PVDC Blister Pack x 10's (Box of 60's and 100's)
Rx
SunGlow Lifescience Private LimitedIndia
Despina Pharma Inc.
DRP-16133
Nov 7, 2029
LecitramLevetiracetam
100 mg/mL (500 mg/5 mL) Solution for Injection (IV Infusion)5 mL USP Type I Clear Transparent Glass Vial along with Grey Bromobutyl Rubber Stopper and Orange Aluminum Flip-off Seal (Box of 25's)
Rx
Gland Pharma LimitedIndia
Pharma-Surrey International, Inc.
DRP-9579
Mar 5, 2031
LentiraLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
The Cathay YSS Distributors Co., Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4583-02
Aug 5, 2028
Lepiva 250Levetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4585-03
Aug 5, 2028
Lepiva-500Levetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4583-04
Aug 5, 2028
LepixaLevetiracetam
100 mg/mL (500 mg/5mL) Solution for Injection (IV)USP Type I glass vial sealed with 20 mm grey rubber stopper and blue aluminum flip-off seal x 5 mL (Box of 1's)
Rx
Aspiro Pharma LimitedIndia
Emcure Pharma PhilippinesImporter: Camber Pharmaceuticals Inc
DRP-9232-03
Oct 31, 2031
LepixaLevetiracetam
100 mg/mL Oral SolutionType III Amber Glass Bottle with Child-Resistant Plastic Cap x 200 mL + 3 mL-Capacity Polypropylene Oral Dosing Syringe (Box of 1's)
Rx
Hetero Labs Limited (Unit Iii)India
Emcure Pharma Philippines Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-9033-03
Jul 30, 2031
Lepixa 1000Levetiracetam
1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Hetero Labs Limited (Unit III)India
Emcure Pharma PhilippinesImporter: Camber Pharmaceuticals Inc
DRP-6433-01
Oct 31, 2031
Lepixa 500Levetiracetam
500 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's)
Rx
Hetero Labs LimitedIndia
Emcure Pharma Philippines Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-6432-02
Nov 30, 2027
LepmedLevetiracetam
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's; Box of 60's)
Rx
Zhejiang Jingxin Pharmaceutical Co. Ltd.China
Blue Medceuticals Marketing Corp.Importer: Medinova Pharmaceutical Inc.
DRP-13585-04
Mar 14, 2028
LepstopLevetiracetam
100 mg/mL (500 mg/5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-Off Cap x 5 mL (Box of 10's)
Rx
Aroma İlaç San. Ltd.Turkey
Importer: Medinova Pharmaceutical, Inc.
DRP-10900
Dec 14, 2026
LeptamLevetiracetam
100 mg/mL (500mg/5mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5ml (Box of 10's)
Rx
Aroma Ilac San. Ltd. StiTurkey
Tamiga Pharmaceuticals SupplyImporter: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac, San. Ve Tic. A.S.
DRP-10900-03
Dec 14, 2026
Leptam TabLevetiracetam
500 mg Film-Coated TabletAlu/ PVC Blister Pack x 10's (Box of 30's)
Rx
Zhejiang Jingxin Pharmaceutical Co. Ltd.China
Tamiga Pharmaceuticals SupplyImporter: Medinova Pharmaceutical Inc.
DRP-13585-02
Mar 14, 2028
Leteram-250Levetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Diafarm Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4585-04
Aug 5, 2028
Leteram-500Levetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4583-06
Aug 5, 2028
LetramLevetiracetam
250 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's Box of 100's
Rx
Hetero Labs LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-6431
Nov 30, 2027
LetramLevetiracetam
500 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's Box of 100's
Rx
Hetero Labs LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-6432
Nov 30, 2027
LevacetamLevetiracetam
100 mg/mL (500 mg/5 mL) Concentrated Solution for Injection ( IM/IV)5mL USP Type I Clear Glass Vial along with Grey Bromobutyl Rubber Stopper and White Alumimun Flip -Off Seal x 10's (Box of 10's)
Rx
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DRP-11425
May 11, 2031
LevacetamLevetiracetam
500 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's)
Rx
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.Importer: OEP Philippines Inc.
DRP-7248-01
Jul 6, 2031
LevcetamLevetiracetam
500 mg/5 mL Solution For I.V. Infusion5 mL USP Type I clear transparent glass vial with gray Bromobutyl rubber stopper & light-blue colour flip-off seal - (Box of 1's & 10's)
Rx
Anhil Parenteral Pvt. Ltd.India
Biophil Medical Equipment and Supplies Trading
DRP-18439
Jul 10, 2031
LevecareLevetiracetam
500 mg Film-Coated TabletAlu-PVDC Blister pack x 10's (Box of 100's)
Rx
Hetero Labs Limited (Unit III)India
Multicare Pharmaceuticals Phils. Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-6432-03
Nov 30, 2027
LevecetamLevetiracetam
100mg/mL Solution for Injection (IV)Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Green Aluminum Flip-Off Seal Cap x 5mL (Box of 1's)
Rx
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-16961
Sep 2, 2030
LevegetLevetiracetam
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)5 mL USP Type I Clear Glass Ampoule (Box of 1's)
Rx
Getz Pharma Pvt. Ltd.Pakistan
Getz Pharma (Phils.), Inc.
DR-XY47793
Mar 10, 2027
LevegetLevetiracetam
1g Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's); and Alu/PVC Blister Pack x 1's (Box of 1's) as Physician Sample
Rx
Getz Pharma Pvt. Ltd.Pakistan
Importer: Getz Pharma (Phils.), Inc.
DR-XY47434
Feb 21, 2028
LevegetLevetiracetam
250mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's)
Rx
Getz Pharma Pvt. Ltd.Pakistan
Importer: Getz Pharma (Phils.), Inc.
DR-XY47432
Mar 6, 2028
LevegetLevetiracetam
500mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's); and Alu/PVC Blister Pack x 1's (Box of 1's) as Physician Sample
Rx
Getz Pharma Pvt. Ltd.Pakistan
Importer: Getz Pharma (Phils.), Inc.
DR-XY47433
Feb 21, 2028
LevegetLevetiracetam
750mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's); and Alu/PVC Blister Pack x 1's (Box of 1's) as Physician Sample
Rx
Getz Pharma Pvt. Ltd.Pakistan
Importer: Getz Pharma (Phils.), Inc.
DR-XY47689
Feb 21, 2028
LevelepticLevetiracetam
1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Bafna Pharmaceuticals LimitedIndia
Medethix, Inc.
DRP-16432
Sep 11, 2030
LevelepticLevetiracetam
250mg Film-Coated TabletAlu/Alu Blister pack x 10's
Rx
—
—
DRP-13283
Feb 2, 2028
LevelepticLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Bafna Pharmaceuticals LimitedIndia
MedEthix, Inc.
DRP-13281
Feb 2, 2028
LevelifeLevetiracetam
500 mg Film-Coated TabletAlu/PVC Blister Pack x 1’s (Box of 1’s) as Physician’s Sample; Alu/PVC Blister Pack x 10’s (Box of 10’s, 30’s, 60’s and 100’s)
Rx
Galen Pharmaceuticals LimitedIndia
Biophil Medical Equipment and Supplies Trading
DRP-18763
Sep 1, 2031
Levellen-PE500Levetiracetam
100mg/mL Concentrated Solution For Iv Infusion5 mL USP Type I clear glass vial, with grey bromobutyl rubber stopper, aluminum seal, and blue flip-off cap (Box of 1's and 10's)
Rx
Penam Biosciences Pvt. Ltd.India
Ollen Pharma Trading Inc.
DRP-18898
Sep 29, 2031
Levensa IVLevetiracetam
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)5 mL-capacity Type I Clear Glass Vial Sealed with Gray Chlorobutyl Rubber Stopper and Aluminum Seal with Pink Flip-off Cap x 1's (Box of 1's and 10's)
Rx
Able Medical Company LimitedThailand
Euro-Care Product Philippines
DRP-18993
Oct 14, 2031
LevephaseLevetiracetam
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Borosilicate Glass Vial with Gray Rubber Stopper and Aluminum Plastic Overseal Cap x 10 mL (Box of 1’s and 10’s)
Rx
Hainan Poly Pharm. Co., Ltd.China
Ambica International Corporation
DRP-11179
Feb 10, 2032
LeveragenLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Eba Generisch Trading Inc.
DRP-16434-02
Mar 11, 2027
LeveramLevetiracetam
1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's)
Rx
Intas Pharmaceuticals LimitedIndia
Endure Medical, Inc.Importer: Singapore Genebio, Inc.
DRP-7514
Nov 21, 2027
LeveramLevetiracetam
250 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's)
Rx
Intas Pharmaceuticals LimitedIndia
Endure Medical, Inc.Importer: Singapore Genebio, Inc.
DRP-7678
Nov 21, 2027
LeveramLevetiracetam
500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's)
Rx
Intas Pharmaceuticals LimitedIndia
Endure Medical, Inc.Importer: Singapore Genebio, Inc.
DRP-7679
Nov 21, 2027
LEVERAPLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-16434-01
Mar 11, 2027
LeveroLevetiracetam
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)USP Type I glass vial sealed with 20 mm grey rubber stopper and blue aluminum flip-off seal x 5 mL (Box of 1's)
Rx
Aspiro Pharma LimitedIndia
Camber Pharmaceuticals, Inc
DRP-9232
Nov 9, 2031
LevesaphLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Sai Parenterals Ltd.India
Nelpa Lifesciences, Inc.
DRP-12687
Jul 31, 2030
LevestalLevetiracetam
100 mg/mL Oral SolutionUSP Type III Amber colored glass bottle with child resistant polypropylene cap x 300 mL (Box of 1's)
Rx
Stallion Laboratories Pvt. LtdIndia
Ambica International Corporation
DRP-17823
Mar 17, 2031
Levestal-500Levetiracetam
500 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Kodapharm Med Corp.Importer: Ambica International Corporation
DRP-10907
Dec 23, 2031
LevesyncLevetiracetam
100 mg / mL Oral SolutionBoston Round Amber Glass Bottle x 300 mL (Box of 1's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Starpharm, Inc.
DRP-16898-02
Aug 11, 2030
Levetigrand 250Levetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. LtdIndia
Grandis Pharma IncorporatedImporter: Pharmakon Biotec Inc.
DRP-13518-02
Mar 3, 2028
Levetigrand 500Levetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Grandis Pharma IncorporatedImporter: Pharmakon Biotec Inc.
DRP-13517-02
Mar 3, 2028
Levetirasaph-AltLevetiracetam
100 mg/mL Concentrated Solution For Iv Infusion5 mL USP Type I clear glass vial, with grey bromobutyl rubber stopper, aluminum seal, and blue flip-off cap (Box of 1's and 10's)
Rx
Althea Phama Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-18899
Sep 29, 2031
LevetraLevetiracetam
500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 60's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Vitalink Health Products, Inc.
DR-XY43111
Dec 19, 2028
Levetramed - 1000Levetiracetam
1 g Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Zhejiang Jingxin Pharmaceutical Co. Ltd.China
Medinova Pharmaceutical Inc.
DRP-13584
Mar 14, 2028
Levetramed - 500Levetiracetam
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Zhejiang Jingxin Pharmaceutical Co. Ltd.China
Medinova Pharmaceutical Inc.
DRP-13585
Mar 14, 2028
LevetrexLevetiracetam
1000mg Film Coated TabletAlu-PVC Blister Pack x 10's
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises, Inc.
DRP-19113
Oct 29, 2031
LevetrexLevetiracetam
250mg Film Coated TabletAlu/PVC blister pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-14241
Aug 2, 2028
LevetrexLevetiracetam
500mg Film Coated TabletAlu/PVC blister pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-14242
Aug 2, 2028
LevetricareLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Medcare PharmaceuticalsImporter: Pharmakon Biotec, Inc.
DRP-13517-07
Mar 3, 2028
LevetroyLevetiracetam
100 mg / mL Concentrate Solution for Injection (IV Infusion)Type I Clear Colorless Flint Ampoule x 5mL in Plastic Tray (Box of 10's)
Rx
Troikaa Pharmaceuticals LimitedIndia
Troikaa Phramaceuticals Philippines, Inc.
DRP-15623
Jun 4, 2029
LevetroyLevetiracetam
100 mg/mL Concentrate Solution for Injection (IV Infusion)5 mL Clear Glass Vial (Ph.Eur. Type I) with 20 mm Bromobutyl Rubber Stopper and 20 mm White Flip off Seal (Box of 1's)
Rx
Troikaa Pharmaceuticals LimitedIndia
Troikaa Pharmaceuticals Philippines Inc.
DR-XY49106
May 21, 2030
LevetroyLevetiracetam
100mg/mL Concentrate Solution for Injection (IV Infusion)5mL Clear Glass Vial (Ph. Eur. Type I) with 20mm Bromobutyl Rubber Stopper anad 20mm White Flip Off Seal (Box of 1's)
Rx
Troikaa Pharmaceuticals LimitedIndia
Troikaa Pharmaceuticals Philippines, Inc.
DRP-16685
May 21, 2030
LevexamLevetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-13518
Mar 3, 2028
LevexamLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-13517
Mar 3, 2028
Leviacet 250Levetiracetam
250 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Zhejiang Jingxin Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-17799
Mar 11, 2031
LevidexLevetiracetam
500 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Delex Pharma International, Inc.Importer: Ambica International Corporation
DRP-10907-03
Dec 23, 2031
LevifarLevetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Healer's Lab (Unit II)India
Pharmakon Biotec Inc.
DRP-16435
Mar 11, 2030
LevinovLevetiracetam
100 mg/ml Solution for Injection (I.V. Infusion)Type I Clear Glass Vial sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Green Flip- off Seal Cap x 1's (Box of 1's and 5's)
Rx
Ratnatris Pharmaceuticals Pvt. Ltd.India
Medinova Pharmaceutical Inc.
DRP-17809
Mar 12, 2031
LevipamLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's); Alu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India 174101
Northmed Pharma and Medical Supplies DistributionImporter: Pharmakon Biotec Inc.
DRP-13517-08
Mar 3, 2028
LevipilLevetiracetam
100 mg/mL Concentrate Solution for IV Infusion5 mL (Net Content) Type I clear and colorless glass vial with 20 mm gray bromobutyl rubber stopper and 20 mm aluminum seal with green plastic flip-off cap (Box of 1's)
Rx
Sun Pharmaceutical Medicare LimitedIndia
Sun Pharma Philippines, Inc.
DRP-11418
May 9, 2028
Levipil 500Levetiracetam
500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's)
Rx
Sun Pharmaceutical Industries Ltd.India
Sun Pharma Philippines, Inc.
DRP-8661
May 9, 2027
Levipil 750Levetiracetam
750 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 50's)
Rx
Sun Pharma Laboratories Ltd.India
Sun Pharma Philippines, Inc.
DRP-8662
Oct 16, 2028
Levipil XR 1000Levetiracetam
1 g Extended Release TabletAlu/Alu PVC Cold forming Blister Pack x 6's (Box of 30's)
Rx
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DR-XY48320
Aug 31, 2027
Levipil XR 1500Levetiracetam
1.5 g Extended Release TabletAlu/Alu PVC Cold forming Blister Pack x 10's (Box of 30's)
Rx
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DR-XY48319
Aug 30, 2027
Levipra 250Levetiracetam
250 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Unison Laboratories Co., Ltd.Thailand
Justright Healthcare Inc.
DR-XY49529
Oct 1, 2030
Levipra 500Levetiracetam
500mg TabletAlu/Alu Blister Pack x 6's (Box of 60's)
Rx
Unison Laboratories Co., Ltd.Thailand
Justright Healthcare Inc.
DR-XY49528
Oct 1, 2030
LevirtigenLevetiracetam
100 mg/mL Oral SolutionBoston Round Amber Glass Bottle x 300 mL (Box of 1's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Eba Generisch Trading Inc.
DRP-16898-03
Aug 11, 2030
LevitLevetiracetam
500 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 60's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DR-XY46913
Jun 23, 2030
LevitLevetiracetam
500 mg Film-Coated TabletBlister Pack x 10's (Box of 60's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-8502
May 28, 2031
Levit IVLevetiracetam
100 mg / mL (500 mg / 5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5 mL (Box of 2's, 4's, and 10's)
Rx
Aroma Ilac San. Ltd. StiTurkey
Innogen Pharmaceuticals, Inc.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac San Ve Tic. A.S.
DRP-10900-07
Dec 14, 2026
Levit IVLevetiracetam
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)USP Type I glass vial sealed with 20 mm grey rubber stopper and blue aluminum flip-off seal x 5 mL (Box of 1's)
Rx
Aspiro Pharma LimitedIndia
Innogen Pharmaceuticals, Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-9232-02
Aug 18, 2031
Levitam 1000Levetiracetam
1 g Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's; Box of 60's)
Rx
Zhejiang Jingxin Pharmaceutical Co. Ltd.China
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13584-01
Mar 14, 2028
Levitam 500Levetiracetam
500 mg Film-Coated TabletAlu/ PVC Blister Pack x 10's (Box of 30's & Box of 60's)
Rx
Zhejiang Jingxin Pharmaceutical Co., Ltd.China
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13585-01
Mar 14, 2028
LevitarLevetiracetam
500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s, 50’s and 100’s)
Rx
Azarias Pharmaceutical Laboratories.Philippines
N/A
DRP-16434
Mar 11, 2027
Levitar-SLevetiracetam
100 mg/mL Oral SolutionBoston Round Amber Glass Bottle x 300 mL (Box of 1's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-16898
Aug 11, 2030
LevitraLevetiracetam
1 g Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Micro Labs LimitedIndia
Brown and Burk Phils., Inc.
DR-XY48225
Jul 26, 2027
LevixamLevetiracetam
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Borosilicate Glass Vial with Gray Rubber Stopper and Aluminum Plastic Overseal Cap x 10 mL (Box of 10’s)
Rx
Hainan Poly Pharm. Co., Ltd.China
Uni-Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-11179-01
Feb 10, 2032
LevixamLevetiracetam
500 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Uni-Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-10907-01
Oct 20, 2037
Levizam 500Levetiracetam
500mg Film-Coated TabletAlu-Clear PVC/PVDC Blister Pack x 10’s (Box of 10’s, 30's, 60's and 100's)
Rx
Sunglow Lifescience Private LimitedIndia
Epione Lifecare Inc.Importer: Despina Pharma Inc.
DRP-16133-01
Nov 7, 2029
LevsezurLevetiracetam
100 mg/mL Oral Solution100 mL and 300 mL Amber Bottle (Box of 1's)
Rx
Novagen Healthcare Private LimitedIndia
Medethix, Inc.
DRP-15069
Apr 4, 2029
LevtrawellLevetiracetam
1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4584-03
Aug 5, 2028
LevtrawellLevetiracetam
100 mg/mL SyrupAmber Colored PET Bottle x 100 mL (Box of 1’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant II)India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4984-01
Dec 11, 2028
LevtrawellLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4583-07
Aug 5, 2028
LevtrazemLevetiracetam
100 mg/mL Solution For Injection (I.V.)USP Type III clear glass vial with grey butyl rubber stopper and aluminum flip off seal x 5 mL (Box of 1's)
Rx
Makcur Laboratories LimitedIndia
Diafarm Inc.
DRP-14900
Feb 6, 2029
LevtraztamLevetiracetam
100 mg/mL (500 mg/5 mL) Solution for Injection (I.V. Infusion)USP Type I Clear Glass Ampoule x 5 mL (Box of 5’s)
Rx
Cooper Pharma LimitedIndia
Ambica International Corporation
DRP-19137
Nov 5, 2031
LezureLevetiracetam
100mg/mL Oral Solution200 mL Type III amber glass bottle with child-resistant plastic cap x 150 mL + 3 mL-capacity PP oral dosing syringe (Box of 1's)
Rx
Hetero Labs Limited (Unit III)India
Camber Pharmaceuticals, Inc.
DRP-9033
Aug 20, 2031
LogufenLevetiracetam
250 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's); Alu/PVC/PVDC Blister Pack x 2's (Physician's Sample)
Rx
Kusum Healthcare Pvt. Ltd.India
Kusum Healthcare Private Limited Branch Office
DR-XY47555
Nov 24, 2031
LogufenLevetiracetam
500 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's Box of 30's; Alu/PVC/PVDC Blister Pack x 2's (as Physician's Sample)
Rx
Kusum Healthcare Pvt. Ltd.India
Kusum Healthcare Private Limited Branch Office
DR-XY47258
May 18, 2031
Lumark-250Levetiracetam
250 mg film-coated TabletAlu/Clear PVC blister pack x 10's (Box of 10's)
Rx
The Searle Company LimitedPakistan
Britton Distributions, Inc.
DRP-4906
Nov 8, 2028
Lumark-500Levetiracetam
500 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
Rx
The Searle Company LimitedPakistan
Britton Distributions, Inc.
DRP-4647
Sep 2, 2028
MalcetamLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 90's)
Rx
PharmEvo (Pvt.) Ltd.Pakistan
Malyka International Trading Corp.Importer: Accesspoint International Trading Inc.
DRP-4816-01
Oct 14, 2028
MasolevLevetiracetam
100 mg/mL (500 mg/5 mL) Solution for Injection (I.V.)5 mL USP Type I clear glass vial (Box of 1's)
Rx
Mason PharmaIndia
Finstad Inc.
DRP-13867
May 5, 2028
MASOSAVELevetiracetam
100 mg/mL (500mg/5mL) Solution for Injection (I.V.)5 mL USP Type I clear glass vial (Box of 1's)
Rx
Mason PharmaIndia.
Savelink Pharma and Trading Co.Importer: Finstad Inc.
DRP-13867-03
May 5, 2028
MyolevLevetiracetam
100 mg/mL (500 mg/5 mL) Concentrate for Solution for IV InfusionUSP Type I clear glass vial x 5 mL (net content) with grey bromobutyl rubber stopper, aluminum seal, and blue flip-off cap (Box of 10’s & 25’s)
Rx
Kwality Pharmaceuticals Ltd.India
Seapharma International, Inc.Importer: Pharma-Surrey International, Inc.
DRP-17876-01
Mar 30, 2031
NeurolevLevetiracetam
250 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's)
Rx
Micro Labs LimitedIndia
Brtown & Burk Philippines Inc.Importer: Brown & Burk Philippines Inc.
DRP-7249
Jan 21, 2031
NeurolevLevetiracetam
500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30s and 100's)
Rx
Micro Labs LimitedIndia
Zuellig Pharma CorporationImporter: OEP Philippines, Inc.
DRP-7248
Jun 16, 2031
NoneLevetiracetam
1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Actimed, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4584-01
Aug 5, 2028
NoneLevetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Actimed, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4585-02
Aug 5, 2028
NoneLevetiracetam
250mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Bafna Pharmaceuticals LimitedIndia
Synmosa Biopharma Philippines Inc.Importer: Medethix, Inc.
DRP-13283-01
Feb 2, 2028
NoneLevetiracetam
500 mg Film-Coated TabletAlu/ Clear PVDC Blister Pack x 10's (Box of 60's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen’s Research, Inc.
DR-XY43110
Dec 19, 2028
NoneLevetiracetam
500 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 60's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DR-XY47087
Oct 20, 2030
NoneLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
—
Reta DrugImporter: Pharmakon Biotec Inc.
DRP-13517-06
Mar 3, 2028
NoneLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
TGP Pharma Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4583-03
Aug 5, 2028
NoneLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4583-09
Aug 5, 2028
NoneLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
PharmEvo (Pvt.) Ltd.Pakistan
Reta DrugImporter: Accesspoint International Trading Inc.
DRP-4816-02
Oct 14, 2028
NoneLevetiracetam
500 mg Film-Coated TabletAluminum/PVC/PCTFE Blister Pack x 10 Tablets (Box of 30's)
Rx
Jubilant Generics LimitedIndia
RiteMED PHILS., INC.
DRP-5940
Jan 22, 2030
NoneLevetiracetam
750 mg Film-coated TabletAlu/Clear PVC Blister Pack x 10's Box of 50's
Rx
Sun Pharmaceutical Industries Ltd.India
Ritemed Phils., Inc.Importer: Sun Pharma Philippines, Inc.
DRP-8662-01
May 9, 2027
NovacetamLevetiracetam
500mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
ACME Formulation Pvt. Ltd.India
Medinova Pharmaceutical, Inc.
DRP-10808
Nov 25, 2026
Racet-SLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Starpharm, Inc.
DRP-16434-03
Mar 11, 2027
Rancetam-1000Levetiracetam
1g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Hetero Labs Limited (Unit III)India
Camber Pharmaceuticals, Inc.
DRP-6433
Nov 22, 2030
RaxetacsLevetiracetam
100 mg/mL (500 mg/5 mL) Concentrate Solution for IV InfusionUSP Type I clear glass vial x 5 mL + grey bromobutyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's and 10's)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-17211
Oct 20, 2031
Reflate 500Levetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's); Alu/Alu Blister Pack x 10's (Box of 100's)
Rx
XL Laboratories Pvt. Ltd.India
Wisenheimer TradingImporter: Ambica International Corporation
DRP-4852
Oct 23, 2028
RenaiorLevetiracetam
100 mg/mL Solution For Injection (IV)Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Yellow Aluminum Flip-off Cap in Plastic Tray x 5 mL (Box of 1's, 5's and 10's)
Rx
Ciron Drugs & PharmaceuticalsIndia
Despina Pharma Inc.
DRP-18383
Jun 29, 2031
SalvetamLevetiracetam
100 mg/mL (500 mg/mL) Solution for Injection (I.V.)5 mL USP Type I clear glass vial (Box of 1's)
Rx
Mason PharmaIndia
Salusa Medical Supplies and Pharmaceuticals IncImporter: Finstad Inc.
DRP-13867-02
May 5, 2028
SeiletamLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-13517-04
Mar 3, 2028
Seiz 500Levetiracetam
500 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's)
Rx
Hetero Labs Limited (Unit III)India
Preventia Healthcare Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-6432-01
Nov 30, 2027
Seiz 500Levetiracetam
500 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Preventia Healthcare Inc.Importer: Ambica International Corporation
DRP-10907-02
Oct 28, 2031
SEIZ OSLevetiracetam
100 mg/mL Oral Solution200 mL Type III amber glass bottle with child-resistant plastic cap x 150 mL + 3 mL-capacity PP oral dosing syringe (Box of 1's)
Rx
Hetero Labs Limited (Unit III)India
Preventia Healthcare Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-9033-02
Sep 11, 2031
SezuvinLevetiracetam
100 mg/mL (500 mg/5 mL) Solution for Injection (I.V.)5 mL USP Type I clear glass vial (Box of 1's)
Rx
Mason PharmaIndia
MDB Pharma TradingImporter: Finstad Inc.
DRP-13867-01
May 5, 2028
TiracezanLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Triple 888 Medical And Pharma Inc.
DRP-16434-05
Mar 11, 2027
TroycetamLevetiracetam
100 mg / mL Concentrate Solution for Injection (IV Infusion)5mL Clear Vial (Ph. Eur. Type I) with 20mm Bromobutyl Rubber Stopper and 20mm White Flip Off Seal (Box of 1's)
Rx
Troikaa Pharmaceuticals LimitedIndia
PSAHM Medpharma TradingImporter: Troikaa Pharmaceuticals Philippiners, Inc.
DRP-16685-01
May 21, 2030
UnbrandedLevetiracetam
1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's)
Rx
Jubilant Generics LimitedIndia
RITEMED PHILS., INC.
DRP-6169
Jun 5, 2031
UnbrandedLevetiracetam
250 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's)
Rx
Micro Labs LimitedSipcot Complex Hosur -635 126 Tamil Nadu India
Brown & Burk Philippines, Inc.Importer: OEP Philippines, Inc.
DRP-7249-01
Jan 21, 2031
Vexlev 100Levetiracetam
100mg/mL Syrup (Grape Flavor)Type III Amber Glass Bottle with Child Resistant Tamper-Evident Screw Cap x 300mL with Oral dosing Syringe (Box of 1's)
Rx
One Pharma Industrial Pharmaceutical Company S.A.Greece
VE Pharma Inc.Trader: Vexxa Lifesciences Limited
DR-XY49496
Sep 4, 2030
Vexlev 250Levetiracetam
250 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 30's)
Rx
Akums Drugs & Pharmaceuticals Ltd.India
VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd
DRP-7027
Dec 9, 2028
Vexlev 500Levetiracetam
500 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s Box of 30’s
Rx
Akums Drugs & Pharmaceuticals Ltd.India
VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd
DRP-XY43069
Dec 6, 2028
Vexlev IVLevetiracetam
100 mg/mL (500 mg/5 mL) Concentrated Solution for IV InfusionType I glass vial x 5mL with grey bromobutyl rubber stopper, aluminum seal and orange flip-off cap (Box of 1's)
Rx
Vexxa Lifesciences LimitedHongkong
Ve Pharma Inc.
DR-XY49428
Jun 27, 2030
XolcetamLevetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Xolvemed Pharma IncorporatedImporter: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4585
Aug 5, 2028
XolvecetamLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Xolvemed Pharma IncorporatedImporter: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4583-10
Aug 5, 2028
ZeiskonLevetiracetam
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets)
Rx
CONSERN PHARMA LIMITEDIndia
Pharmakon Biotec Inc.Trader: Neer Life Sciences
DRP-14264
Aug 4, 2028
ZoleviLevetiracetam
1g Film-Coated tabletAlu/Alu Blister Pack x 10's Box of 60's
Rx
Lek Pharmaceuticals D.D.Slovenia
Natrapharm, Inc.Importer: Sandoz Philippines Corporation
DRP-5280-01
Apr 23, 2029
ZoleviLevetiracetam
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's)
Rx
Lek Pharmaceuticals D.DSlovenia
Natrapharm Inc.Importer: Sandoz Philippines Corporation
DRP-7486-01
Feb 13, 2029
ZoleviLevetiracetam
500mg Film-Coated tabletAlu/Alu Blister Pack x 10's (Box of 60's)
Rx
LEK PHARMACEUTICALS D.DSlovenia
Natrapharm, Inc.Importer: Sandoz Philippines Corporation
DRP-7484-01
Feb 13, 2029
(no brand name)Levetiracetam.
1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Bafna Pharmaceuticals LimitedIndia
Medethix, Inc.
DRP-16431
Mar 10, 2030
(no brand name)Levetiracetam
100 mg/ mL Concentrate for Solution for IV InfusionSP type I glass vial with dark grey bromobutyl rubber stopper and golden yellow flip-off aluminum seal x 5 mL (Box of 1's)
Rx
Mylan Laboratories Limited (Hosur Sterile Facility)India
Viatris Pharmaceuticals, Inc.
DR-XY48845
Aug 14, 2028
(no brand name)Levetiracetam
100 mg/mL (500 mg/5 mL) Concentrate Solution For Infusion (IV)Type I Glass Vial sealed with rubber stopper and aluminum with blue flip off cap x 5 mL (Box of 10's)
Rx
Beijing Sciecure Pharmaceutical Co., Ltd.China
Block 20 Pharma Trading
DRP-13122
Dec 5, 2027
(no brand name)Levetiracetam
100 mg/mL (500 mg/5 mL) Concentrate Solution for IV Infusion5 mL (net content) in 7.5 mL USP Type I Clear Glass Clear Vial with Bromo Butyl Rubber Plug and Sealed with White Flip-Seal (Box of 1's)
Rx
Skymap Healthcare Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-16820
Jul 15, 2030
(no brand name)Levetiracetam
100 mg/mL Concentrate for Solution for Infusion (IV)Type I glass vial x 5 mL (net content), with grey bromobutyl rubber stopper, alumminum seal and orange flip-off cap (Box of 10's)
Rx
Pharmathen SAGreece
Saifen Drugs Philippines Inc.
DR-XY49449
Jul 15, 2030
(no brand name)Levetiracetam
100 mg/mL Concentrate For Solution For Iv Infusion5 mL USP Type I Clear Glass Vial (Box of 1's and 10's)
Rx
Gland Pharma LimitedIndia
Trader: Pfizer, Inc.
DRP-46035
Oct 2, 2027
(no brand name)Levetiracetam
100 mg/mL Oral Solution (Grape Flavor)Wide-mouth, boston round, amber glass bottle x 60 mL, 125 mL, 150 mL and 300 mL (Box of 1's)
Rx
Lifesquare Laboratories, Inc.Philippines
—
DRP-13070
Nov 25, 2027
(no brand name)Levetiracetam
100mg/mL Oral Solution100 mL and 300 mL Amber Bottle (Box of 1's)
Rx
Novagen Healthcare Private LimitedIndia
Medethix, Inc.
DRP-15070
Apr 4, 2029
(no brand name)Levetiracetam
250mg Film-Coated TabletAlu/Alu Blister pack x 10's
Rx
—
—
DRP-13284
Jan 18, 2028
(no brand name)Levetiracetam
500mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Bafna Pharmaceuticals LimitedIndia
MedEthix, Inc.
DRP-13282
Jan 18, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS 250 mg, 500 mg, 750 mg, and 1000 mg film-coated, scored tablets (3) 100 mg/mL solution (3) KEPPRA Tablets 250 mg: blue, oblong-shaped, scored, film-coated, and debossed with "ucb 250" on one side 500 mg: yellow, oblong-shaped, scored, film-coated, and debossed with "ucb 500" on one side 750 mg: orange, oblong-shaped, scored, film-coated, and debossed with "ucb 750" on one side 1000 mg: white, oblong-shaped, scored, film-coated, and debossed with "ucb 1000" on one side KEPPRA Oral Solution 100 mg/mL: a clear, colorless, grape-flavored liquid

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Behavioral abnormalities including psychotic symptoms, suicidal ideation, irritability, and aggressive behavior have been observed; monitor patients for psychiatric signs and symptoms (5.1)
  • Suicidal Behavior and Ideation: Monitor patients for new or worsening depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior (5.2)
  • Monitor for somnolence and fatigue and advise patients not to drive or operate machinery until they have gained sufficient experience on KEPPRA (5.3)
  • Serious Dermatological Reactions: Discontinue KEPPRA at the first sign of rash unless clearly not drug related (5.5)
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity: Discontinue if no alternative etiology (5.6)
  • Coordination Difficulties: Monitor for ataxia, abnormal gait, and incoordination. Advise patients to not drive or operate machinery until they have gained experience on KEPPRA (5.7)
  • Withdrawal Seizures: KEPPRA must be gradually withdrawn (5.8)
5.1 Behavioral Abnormalities and Psychotic Symptoms

5.1 Behavioral Abnormalities and Psychotic Symptoms KEPPRA may cause behavioral abnormalities and psychotic symptoms. Patients treated with KEPPRA should be monitored for psychiatric signs and symptoms. Behavioral abnormalities In clinical studies, 13% of adult KEPPRA-treated patients and 38% of pediatric KEPPRA-treated patients (4 to 16 years of age) compared to 6% and 19% of adult and pediatric placebo-treated patients, experienced non-psychotic behavioral symptoms (reported as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, hyperkinesias, irritability, nervousness, neurosis, and personality disorder).

A randomized double-blind, placebo-controlled study was performed to assess the neurocognitive and behavioral effects of KEPPRA as adjunctive therapy in pediatric patients (4 to 16 years of age). The results from an exploratory analysis indicated a worsening in KEPPRA-treated patients on aggressive behavior (one of eight behavior dimensions) as measured in a standardized and systematic way using a validated instrument, the Achenbach Child Behavior Checklist (CBCL/6-18).

In clinical studies in pediatric patients 1 month to < 4 years of age, irritability was reported in 12% of the KEPPRA-treated patients compared to 0% of placebo-treated patients. In clinical studies, 1.7% of adult KEPPRA-treated patients discontinued treatment due to behavioral adverse reactions, compared to 0.2% of placebo-treated patients.

The treatment dose was reduced in 0.8% of adult KEPPRA-treated patients and in 0.5% of placebo-treated patients. Overall, 11% of KEPPRA-treated pediatric patients experienced behavioral symptoms associated with discontinuation or dose reduction, compared to 6% of placebo-treated patients. Psychotic symptoms In clinical studies, 1% of KEPPRA-treated adult patients, 2% of KEPPRA-treated pediatric patients 4 to 16 years of age, and 17% of KEPPRA-treated pediatric patients 1 month to <4 years of age experienced psychotic symptoms, compared to 0.2%, 2%, and 5% in the corresponding age groups treated with placebo.

In a controlled study that assessed the neurocognitive and behavioral effects of KEPPRA in pediatric patients 4 to 16 years of age, 1.6% of KEPPRA-treated patients experienced paranoia, compared to 0% of placebo-treated patients. In the same study, 3.1% of KEPPRA-treated patients experienced confusional state, compared to 0% of placebo-treated patients [see Use in Specific Populations (8.4)].

In clinical studies, two (0.3%) KEPPRA-treated adult patients were hospitalized and their treatment was discontinued due to psychosis. Both events, reported as psychosis, developed within the first week of treatment and resolved within 1 to 2 weeks following treatment discontinuation. There was no difference between drug and placebo-treated patients in the incidence of the pediatric patients who discontinued treatment due to psychotic and non-psychotic adverse reactions.

5.2 Suicidal Behavior and Ideation

5.2 Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including KEPPRA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.

There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed.

Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication.

The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. Table 2 shows absolute and relative risk by indication for all evaluated AEDs. Table 2: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis Indication Placebo Patients with Events Per 1000 Patients Drug Patients with Events Per 1000 Patients Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients Risk Difference: Additional Drug Patients with Events Per 1000 Patients Epilepsy 1.0 3.4 3.5 2.4 Psychiatric 5.7 8.5 1.5 2.9 Other 1.0 1.8 1.9 0.9 Total 2.4 4.3 1.8 1.9 The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing KEPPRA or any other AED must balance the risk of suicidal thoughts or behaviors with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.

Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

5.3 Somnolence and Fatigue

5.3 Somnolence and Fatigue KEPPRA may cause somnolence and fatigue. Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on KEPPRA to gauge whether it adversely affects their ability to drive or operate machinery. Somnolence In controlled trials of adult patients with epilepsy experiencing partial-onset seizures, 15% of KEPPRA-treated patients reported somnolence, compared to 8% of placebo-treated patients.

There was no clear dose response up to 3000 mg/day. In a study where there was no titration, about 45% of patients receiving 4000 mg/day reported somnolence. The somnolence was considered serious in 0.3% of KEPPRA-treated patients, compared to 0% in the placebo group. About 3% of KEPPRA-treated patients discontinued treatment due to somnolence, compared to 0.7% of placebo-treated patients.

In 1.4% of KEPPRA-treated patients and 0.9% of placebo-treated patients, the dose was reduced, while 0.3% of the KEPPRA-treated patients were hospitalized due to somnolence. Asthenia In controlled clinical studies of adult patients with epilepsy experiencing partial-onset seizures, 15% of KEPPRA-treated patients reported asthenia, compared to 9% of placebo-treated patients.

Treatment was discontinued due to asthenia in 0.8% of KEPPRA-treated patients as compared to 0.5% of placebo-treated patients. In 0.5% of KEPPRA-treated patients and in 0.2% of placebo-treated patients, the dose was reduced due to asthenia. Somnolence and asthenia occurred most frequently within the first 4 weeks of treatment.

In general, the incidences of somnolence and fatigue in the pediatric partial-onset seizure studies, and in pediatric and adult myoclonic and primary generalized tonic-clonic seizure studies were comparable to those of the adult partial-onset seizure studies.

5.4 Anaphylaxis and Angioedema

5.4 Anaphylaxis and Angioedema KEPPRA can cause anaphylaxis or angioedema after the first dose or at any time during treatment. Signs and symptoms in cases reported in the postmarketing setting have included hypotension, hives, rash, respiratory distress, and swelling of the face, lip, mouth, eye, tongue, throat, and feet.

In some reported cases, reactions were life-threatening and required emergency treatment. If a patient develops signs or symptoms of anaphylaxis or angioedema, KEPPRA should be discontinued and the patient should seek immediate medical attention. KEPPRA should be discontinued permanently if a clear alternative etiology for the reaction cannot be established [see Contraindications (4)].

5.5 Serious Dermatological Reactions

5.5 Serious Dermatological Reactions Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in both pediatric and adult patients treated with KEPPRA. The median time of onset is reported to be 14 to 17 days, but cases have been reported at least four months after initiation of treatment.

Recurrence of the serious skin reactions following rechallenge with KEPPRA has also been reported. KEPPRA should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered.

5.6 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

5.6 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including KEPPRA. These events can be fatal or life-threatening, particularly if diagnosis and treatment do not occur as early as possible.

DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection. Eosinophilia is often present.

Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately.

KEPPRA should be discontinued if an alternative etiology for the signs or symptoms cannot be established [see Contraindications (4)].

5.7 Coordination Difficulties

5.7 Coordination Difficulties KEPPRA may cause coordination difficulties. In controlled clinical studies in adult patients with partial-onset seizure studies, 3.4% of adult KEPPRA-treated patients experienced coordination difficulties, (reported as either ataxia, abnormal gait, or incoordination) compared to 1.6% of placebo-treated patients.

A total of 0.4% of patients in controlled clinical studies discontinued KEPPRA treatment due to ataxia, compared to 0% of placebo-treated patients. In 0.7% of KEPPRA-treated patients and in 0.2% of placebo-treated patients, the dose was reduced due to coordination difficulties, while one of the KEPPRA-treated patients was hospitalized due to worsening of pre-existing ataxia.

These events occurred most frequently within the first 4 weeks of treatment. Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on KEPPRA to gauge whether it could adversely affect their ability to drive or operate machinery.

5.8 Withdrawal Seizures

5.8 Withdrawal Seizures As with most antiepileptic drugs, KEPPRA should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. If withdrawal is needed because of a serious adverse reaction, rapid discontinuation can be considered.

5.9 Hematologic Abnormalities

5.9 Hematologic Abnormalities KEPPRA can cause hematologic abnormalities. Hematologic abnormalities occurred in clinical trials and included decreases in white blood cell (WBC), neutrophil, and red blood cell (RBC) counts; decreases in hemoglobin and hematocrit; and increases in eosinophil counts. Cases of agranulocytosis, pancytopenia, and thrombocytopenia have been reported in the postmarketing setting.

A complete blood count is recommended in patients experiencing significant weakness, pyrexia, recurrent infections, or coagulation disorders. Partial-Onset Seizures Adults Minor, but statistically significant, decreases compared to placebo in total mean RBC count (0.03 × 106/mm3), mean hemoglobin (0.09 g/dL), and mean hematocrit (0.38%), were seen in KEPPRA-treated patients in controlled trials.

A total of 3.2% of KEPPRA-treated and 1.8% of placebo-treated patients had at least one possibly significant (≤2.8 × 10 9 /L) decreased WBC, and 2.4% of KEPPRA-treated and 1.4% of placebo-treated patients had at least one possibly significant (≤1.0 × 10 9 /L) decreased neutrophil count. Of the KEPPRA-treated patients with a low neutrophil count, all but one rose towards or to baseline with continued treatment.

No patient was discontinued secondary to low neutrophil counts. Pediatric Patients 4 Years to < 16 Years Statistically significant decreases in WBC and neutrophil counts were seen in KEPPRA-treated patients as compared to placebo. The mean decreases from baseline in the KEPPRA-treated group were -0.4 × 10 9 /L and -0.3 × 10 9 /L, respectively, whereas there were small increases in the placebo group.

Mean relative lymphocyte counts increased by 1.7% in KEPPRA-treated patients, compared to a decrease of 4% in placebo patients (statistically significant). In the controlled trial, more KEPPRA-treated patients had a possibly clinically significant abnormally low WBC value (3% of KEPPRA-treated patients versus 0% of placebo-treated patients), however, there was no apparent difference between treatment groups with respect to neutrophil count (5% of KEPPRA-treated patients versus 4.2% of placebo-treated patients).

No patient was discontinued secondary to low WBC or neutrophil counts. In the controlled cognitive and neuropsychological safety study, 5 patients (8.6%) in the KEPPRA-treated group and two patients (6.1%) in the placebo-treated group had high eosinophil count values that were possibly clinically significant (≥10% or ≥0.7 × 10 9 /L).

5.10 Increase in Blood Pressure

5.10 Increase in Blood Pressure In a randomized, placebo-controlled study in patients 1 month to <4 years of age, a significantly higher risk of increased diastolic blood pressure was observed in the KEPPRA-treated patients (17%), compared to the placebo-treated patients (2%). There was no overall difference in mean diastolic blood pressure between the treatment groups.

This disparity between the KEPPRA and placebo treatment groups was not observed in the studies of older children or in adults. Monitor patients 1 month to <4 years of age for increases in diastolic blood pressure.

5.11 Seizure Control During Pregnancy

5.11 Seizure Control During Pregnancy Physiological changes may gradually decrease plasma levels of levetiracetam throughout pregnancy. This decrease is more pronounced during the third trimester. It is recommended that patients be monitored carefully during pregnancy. Close monitoring should continue through the postpartum period especially if the dose was changed during pregnancy.

Adverse reactions

Common

  • Somnolence, asthenia, dizziness, infection (adults)
  • Children: fatigue, aggression, nasal congestion, decreased appetite, irritability

Serious

  • Behavioral abnormalities, psychotic symptoms, suicidal ideation
  • Somnolence and coordination difficulties
  • Anaphylaxis, angioedema
  • Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS
  • Withdrawal seizures if stopped abruptly
  • Hematologic abnormalities
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following adverse reactions are discussed in more details in other sections of labeling: Behavior Abnormalities and Psychotic Symptoms [see Warnings and Precautions (5.1)] Suicidal Behavior and Ideation [see Warnings and Precautions (5.2)] Somnolence and Fatigue [see Warnings and Precautions (5.3)] Anaphylaxis and Angioedema [see Warnings and Precautions (5.4)] Serious Dermatological Reactions [see Warnings and Precautions (5.5)] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions (5.6)] Coordination Difficulties [see Warnings and Precautions (5.7)] Hematologic Abnormalities [see Warnings and Precautions (5.9)] Increase in Blood Pressure [see Warnings and Precautions (5.10)] Most common adverse reactions (incidence ≥ 5% more than placebo) include: Adult patients: somnolence, asthenia, infection and dizziness (6.1)
  • Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-844-599-2273 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Partial-Onset Seizures Adults In controlled clinical studies in adults with partial-onset seizures [see Clinical Studies (14.1)], the most common adverse reactions in patients receiving KEPPRA in combination with other AEDs, for events with rates greater than placebo, were somnolence, asthenia, infection, and dizziness.

Of the most common adverse reactions in adults experiencing partial-onset seizures, asthenia, somnolence, and dizziness occurred predominantly during the first 4 weeks of treatment with KEPPRA. Table 3 lists adverse reactions that occurred in at least 1% of adult epilepsy patients receiving KEPPRA in placebo-controlled studies and were numerically more common than in patients treated with placebo.

In these studies, either KEPPRA or placebo was added to concurrent AED therapy. Table 3: Adverse Reactions in Pooled Placebo-Controlled, Adjunctive Studies in Adults Experiencing Partial-Onset Seizures KEPPRA (N=769) % Placebo (N=439) % Asthenia 15 9 Somnolence 15 8 Headache 14 13 Infection 13 8 Dizziness 9 4 Pain 7 6 Pharyngitis 6 4 Depression 4 2 Nervousness 4 2 Rhinitis 4 3 Anorexia 3 2 Ataxia 3 1 Vertigo 3 1 Amnesia 2 1 Anxiety 2 1 Cough Increased 2 1 Diplopia 2 1 Emotional Lability 2 0 Hostility 2 1 Paresthesia 2 1 Sinusitis 2 1 In controlled adult clinical studies, 15% of patients receiving KEPPRA and 12% receiving placebo either discontinued or had a dose reduction as a result of an adverse reaction.

Table 4 lists the most common (>1%) adverse reactions that resulted in discontinuation or dose reduction and that occurred more frequently in KEPPRA-treated patients than in placebo-treated patients. Table 4: Adverse Reactions that Resulted in Discontinuation or Dose Reduction in Placebo-Controlled Studies in Adult Patients Experiencing Partial-Onset Seizures Adverse Reaction KEPPRA (N=769) % Placebo (N=439) % Somnolence 4 2 Dizziness 1 0 Pediatric Patients 4 Years to <16 Years The adverse reaction data presented below was obtained from a pooled analysis of two controlled pediatric clinical studies in pediatric patients 4 to 16 years of age with partial-onset seizures.

The most common adverse reactions in pediatric patients receiving KEPPRA in combination with other AEDs, for events with rates greater than placebo, were fatigue, aggression, nasal congestion, decreased appetite, and irritability. Table 5 lists adverse reactions from the pooled pediatric controlled studies (4 to 16 years of age) that occurred in at least 2% of pediatric KEPPRA-treated patients and were numerically more common than in pediatric patients treated with placebo.

In these studies, either KEPPRA or placebo was added to concurrent AED therapy. Table 5: Adverse Reactions in Pooled Placebo-Controlled, Adjunctive Studies in Pediatric Patients Ages 4 to 16 Years Experiencing Partial-Onset Seizures KEPPRA (N=165) % Placebo (N=131) % Headache 19 15 Nasopharyngitis 15 12 Vomiting 15 12 Somnolence 13 9 Fatigue 11 5 Aggression 10 5 Cough 9 5 Nasal Congestion 9 2 Upper Abdominal Pain 9 8 Decreased Appetite 8 2 Abnormal Behavior 7 4 Dizziness 7 5 Irritability 7 1 Pharyngolaryngeal Pain 7 4 Diarrhea 6 2 Lethargy 6 5 Insomnia 5 3 Agitation 4 1 Anorexia 4 3 Head Injury 4 0 Altered Mood 3 1 Constipation 3 1 Contusion 3 1 Depression 3 1 Fall 3 2 Influenza 3 1 Affect Lability 2 1 Anxiety 2 1 Arthralgia 2 0 Confusional State 2 0 Conjunctivitis 2 0 Ear Pain 2 1 Gastroenteritis 2 0 Joint Sprain 2 1 Mood Swings 2 1 Neck Pain 2 1 Rhinitis 2 0 Sedation 2 1 In the controlled pooled pediatric clinical studies in patients 4-16 years of age, 7% of patients receiving KEPPRA and 9% receiving placebo discontinued as a result of an adverse reaction.

Pediatric Patients 1 Month to < 4 Years In the 7-day, controlled pediatric clinical study in children 1 month to less than 4 years of age with partial-onset seizures, the most common adverse reactions in patients receiving KEPPRA in combination with other AEDs, for events with rates greater than placebo, were somnolence and irritability. Because of the shorter exposure period, incidences of adverse reactions are expected to be lower than in other pediatric studies in older patients.

Therefore, other controlled pediatric data, presented above, should also be considered to apply to this age group. Table 6 lists adverse reactions that occurred in at least 5% of pediatric epilepsy patients (ages 1 month to < 4 years) treated with KEPPRA in the placebo-controlled study and were numerically more common than in patients treated with placebo.

In this study, either KEPPRA or placebo was added to concurrent AED therapy. Table 6: Adverse Reactions in a Placebo-Controlled, Adjunctive Study in Pediatric Patients Ages 1 Month to < 4 Years Experiencing Partial-Onset Seizures KEPPRA (N=60) % Placebo (N=56) % Somnolence 13 2 Irritability 12 0 In the 7-day controlled pediatric clinical study in patients 1 month to < 4 years of age, 3% of patients receiving KEPPRA and 2% receiving placebo either discontinued or had a dose reduction as a result of an adverse reaction.

There was no adverse reaction that resulted in discontinuation for more than one patient. Myoclonic Seizures Although the pattern of adverse reactions in this study seems somewhat different from that seen in patients with partial-onset seizures, this is likely due to the much smaller number of patients in this study compared to partial seizure studies.

The adverse reaction pattern for patients with JME is expected to be essentially the same as for patients with partial seizures. In the controlled clinical study in patients 12 years of age and older with myoclonic seizures [see Clinical Studies (14.2)], the most common adverse reactions in patients receiving KEPPRA in combination with other AEDs, for events with rates greater than placebo, were somnolence, neck pain, and pharyngitis.

Table 7 lists adverse reactions that occurred in at least 5% of juvenile myoclonic epilepsy patients experiencing myoclonic seizures treated with KEPPRA and were numerically more common than in patients treated with placebo. In this study, either KEPPRA or placebo was added to concurrent AED therapy. Table 7: Adverse Reactions in a Placebo-Controlled, Adjunctive Study in Patients 12 Years of Age and Older with Myoclonic Seizures KEPPRA (N=60) % Placebo (N=60) % Somnolence 12 2 Neck pain 8 2 Pharyngitis 7 0 Depression 5 2 Influenza 5 2 Vertigo 5 3 In the placebo-controlled study, 8% of patients receiving KEPPRA and 2% receiving placebo either discontinued or had a dose reduction as a result of an adverse reaction.

The adverse reactions that led to discontinuation or dose reduction and that occurred more frequently in KEPPRA-treated patients than in placebo-treated patients are presented in Table 8. Table 8: Adverse Reactions that Resulted in Discontinuation or Dose Reduction in a Placebo-Controlled Study in Patients with Juvenile Myoclonic Epilepsy Adverse Reaction KEPPRA (N=60) % Placebo (N=60) % Anxiety 3 2 Depressed mood 2 0 Depression 2 0 Diplopia 2 0 Hypersomnia 2 0 Insomnia 2 0 Irritability 2 0 Nervousness 2 0 Somnolence 2 0 Primary Generalized Tonic-Clonic Seizures Although the pattern of adverse reactions in this study seems somewhat different from that seen in patients with partial-onset seizures, this is likely due to the much smaller number of patients in this study compared to partial seizure studies.

The adverse reaction pattern for patients with primary generalized tonic-clonic (PGTC) seizures is expected to be essentially the same as for patients with partial seizures. In the controlled clinical study that included patients 4 years of age and older with PGTC seizures [see Clinical Studies (14.3)], the most common adverse reaction in patients receiving KEPPRA in combination with other AEDs, for events with rates greater than placebo, was nasopharyngitis.

Table 9 lists adverse reactions that occurred in at least 5% of idiopathic generalized epilepsy patients experiencing PGTC seizures treated with KEPPRA and were numerically more common than in patients treated with placebo. In this study, either KEPPRA or placebo was added to concurrent AED therapy. Table 9: Adverse Reactions in a Placebo-Controlled, Adjunctive Study in Patients 4 Years of Age and Older with PGTC Seizures KEPPRA (N=79) % Placebo (N=84) % Nasopharyngitis 14 5 Fatigue 10 8 Diarrhea 8 7 Irritability 6 2 Mood swings 5 1 In the placebo-controlled study, 5% of patients receiving KEPPRA and 8% receiving placebo either discontinued or had a dose reduction during the treatment period as a result of an adverse reaction.

This study was too small to adequately characterize the adverse reactions that could be expected to result in discontinuation of treatment in this population. It is expected that the adverse reactions that would lead to discontinuation in this population would be similar to those resulting in discontinuation in other epilepsy trials (see tables 4 and 8).

In addition, the following adverse reactions were seen in other controlled adult studies of KEPPRA: balance disorder, disturbance in attention, eczema, memory impairment, myalgia, and blurred vision. Comparison of Gender, Age and Race The overall adverse reaction profile of KEPPRA was similar between females and males. There are insufficient data to support a statement regarding the distribution of adverse reactions by age and race.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of KEPPRA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been reported in patients receiving marketed KEPPRA worldwide.

The listing is alphabetized: abnormal liver function test, acute kidney injury, anaphylaxis, angioedema, agranulocytosis, choreoathetosis, drug reaction with eosinophilia and systemic symptoms (DRESS), dyskinesia, erythema multiforme, hepatic failure, hepatitis, hyponatremia, muscular weakness, obsessive-compulsive disorders (OCD), pancreatitis, pancytopenia (with bone marrow suppression identified in some of these cases), panic attack, thrombocytopenia, weight loss, and worsening of seizures including in patients with SCN8A mutations. Alopecia has been reported with KEPPRA use; recovery was observed in majority of cases where KEPPRA was discontinued.

Adverse reaction frequency tables (US label) US FDA label
Table 3: Adverse Reactions in Pooled Placebo-Controlled, Adjunctive Studies in Adults Experiencing Partial-Onset Seizures
KEPPRA (N=769) % Placebo (N=439) %
Asthenia159
Somnolence158
Headache1413
Infection138
Dizziness94
Pain76
Pharyngitis64
Depression42
Nervousness42
Rhinitis43
Anorexia32
Ataxia31
Vertigo31
Amnesia21
Anxiety21
Cough Increased21
Diplopia21
Emotional Lability20
Hostility21
Paresthesia21
Sinusitis21
Table 4: Adverse Reactions that Resulted in Discontinuation or Dose Reduction in Placebo-Controlled Studies in Adult Patients Experiencing Partial-Onset Seizures
Adverse ReactionKEPPRA (N=769) % Placebo (N=439) %
Somnolence42
Dizziness10
Table 5: Adverse Reactions in Pooled Placebo-Controlled, Adjunctive Studies in Pediatric Patients Ages 4 to 16 Years Experiencing Partial-Onset Seizures
KEPPRA (N=165) % Placebo (N=131) %
Headache1915
Nasopharyngitis1512
Vomiting1512
Somnolence139
Fatigue115
Aggression105
Cough95
Nasal Congestion92
Upper Abdominal Pain98
Decreased Appetite82
Abnormal Behavior74
Dizziness75
Irritability71
Pharyngolaryngeal Pain74
Diarrhea62
Lethargy65
Insomnia53
Agitation41
Anorexia43
Head Injury40
Altered Mood31
Constipation31
Contusion31
Depression31
Fall32
Influenza31
Affect Lability21
Anxiety21
Arthralgia20
Confusional State20
Conjunctivitis20
Ear Pain21
Gastroenteritis20
Joint Sprain21
Mood Swings21
Neck Pain21
Rhinitis20
Sedation21
Table 6: Adverse Reactions in a Placebo-Controlled, Adjunctive Study in Pediatric Patients Ages 1 Month to < 4 Years Experiencing Partial-Onset Seizures
KEPPRA (N=60) % Placebo (N=56) %
Somnolence132
Irritability120
Table 7: Adverse Reactions in a Placebo-Controlled, Adjunctive Study in Patients 12 Years of Age and Older with Myoclonic Seizures
KEPPRA (N=60) % Placebo (N=60) %
Somnolence122
Neck pain82
Pharyngitis70
Depression52
Influenza52
Vertigo53
Table 8: Adverse Reactions that Resulted in Discontinuation or Dose Reduction in a Placebo-Controlled Study in Patients with Juvenile Myoclonic Epilepsy
Adverse ReactionKEPPRA (N=60) % Placebo (N=60) %
Anxiety32
Depressed mood20
Depression20
Diplopia20
Hypersomnia20
Insomnia20
Irritability20
Nervousness20
Somnolence20
Table 9: Adverse Reactions in a Placebo-Controlled, Adjunctive Study in Patients 4 Years of Age and Older with PGTC Seizures
KEPPRA (N=79) % Placebo (N=84) %
Nasopharyngitis145
Fatigue108
Diarrhea87
Irritability62
Mood swings51

Monitoring parameters

  • Kidney function (CrCl) to set the dose. Seizure control. Behavioral changes, mood, suicidal thinking; somnolence and coordination problems. Avoid abrupt withdrawal. Kidney
  • Creatinine clearance for dosing
  • Mood and behavior
  • Seizure control
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), including KEPPRA, during pregnancy. Encourage women who are taking KEPPRA during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/.

Risk Summary Prolonged experience with KEPPRA in pregnant women has not identified a drug-associated risk of major birth defects or miscarriage, based on published literature, which includes data from pregnancy registries and reflects experience over two decades [see Human Data]. In animal studies, levetiracetam produced developmental toxicity (increased embryofetal and offspring mortality, increased incidences of fetal structural abnormalities, decreased embryofetal and offspring growth, neurobehavioral alterations in offspring) at doses similar to human therapeutic doses [see Animal Data].

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Levetiracetam blood levels may decrease during pregnancy [see Warnings and Precautions (5.11)].

Physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester. Dose adjustments may be necessary to maintain clinical response. Data Human Data While available studies cannot definitively establish the absence of risk, data from the published literature and pregnancy registries have not established an association with levetiracetam use during pregnancy and major birth defects or miscarriage.

Animal Data When levetiracetam (0, 400, 1200, or 3600 mg/kg/day) was administered orally to pregnant rats during the period of organogenesis, reduced fetal weights and increased incidence of fetal skeletal variations were observed at the highest dose tested. There was no evidence of maternal toxicity. The no-effect dose for adverse effects on embryofetal developmental in rats (1200 mg/kg/day) is approximately 4 times the maximum recommended human dose (MRHD) of 3000 mg on a body surface area (mg/m 2) basis.

Oral administration of levetiracetam (0, 200, 600, or 1800 mg/kg/day) to pregnant rabbits during the period of organogenesis resulted in increased embryofetal mortality and incidence of fetal skeletal variations at the mid and high dose and decreased fetal weights and increased incidence of fetal malformations at the high dose, which was associated with maternal toxicity. The no-effect dose for adverse effects on embryofetal development in rabbits (200 mg/kg/day) is approximately equivalent to the MRHD on a mg/m 2 basis.

Oral administration of levetiracetam (0, 70, 350, or 1800 mg/kg/day) to female rats throughout pregnancy and lactation led to an increased incidence of fetal skeletal variations, reduced fetal body weight, and decreased growth in offspring at the mid and high doses and increased pup mortality and neurobehavioral alterations in offspring at the highest dose tested. There was no evidence of maternal toxicity.

The no-effect dose for adverse effects on pre- and postnatal development in rats (70 mg/kg/day) is less than the MRHD on a mg/m 2 basis. Oral administration of levetiracetam to rats during the latter part of gestation and throughout lactation produced no adverse developmental or maternal effects at doses of up to 1800 mg/kg/day (6 times the MRHD on a mg/m 2 basis).

Mechanism of action

12.1 Mechanism of Action The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis.

Although the molecular significance of levetiracetam binding to SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Effects on QTc Interval The effect of KEPPRA on QTc prolongation was evaluated in a randomized, double-blind, positive-controlled (moxifloxacin 400 mg) and placebo-controlled crossover study of KEPPRA (1000 mg or 5000 mg) in 52 healthy subjects. The upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc was below 10 milliseconds. Therefore, there was no evidence of significant QTc prolongation in this study.

Pharmacokinetics

Key PK parameters

Bioavailability100%
Time to peakAbout 1 hour
Half-life7 ± 1 hours
Half-life in kidney failure (ESKD) kidneyProlonged; total clearance 70% lower in anuric ESRD (label)
Protein bindingUnder 10%
Metabolism (CYP, transporters)Enzymatic hydrolysis (not CYP) to inactive ucb L057
Active metabolitesNone
Renal excretion kidney66% unchanged in urine
Dialyzability kidneyYes (about 50% in 4 hours; label)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.

Levetiracetam is eliminated from the systemic circulation by renal excretion as unchanged drug which represents 66% of administered dose.

The total body clearance is 0.96 mL/min/kg and the renal clearance is 0.6 mL/min/kg.

The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption.

The metabolite ucb L057 is excreted by glomerular filtration and active tubular secretion with a renal clearance of 4 mL/min/kg.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The pharmacokinetics of levetiracetam are similar when used as monotherapy or as adjunctive therapy for the treatment of partial-onset seizures. Absorption and Distribution Absorption of levetiracetam is rapid, with peak plasma concentrations occurring in about an hour following oral administration in fasted subjects.

The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption. Food does not affect the extent of absorption of levetiracetam but it decreases C max by 20% and delays T max by 1.5 hours. The pharmacokinetics of levetiracetam are linear over the dose range of 500-5000 mg.

Steady state is achieved after 2 days of multiple twice-daily dosing. Levetiracetam and its major metabolite are less than 10% bound to plasma proteins; clinically significant interactions with other drugs through competition for protein binding sites are therefore unlikely. Metabolism Levetiracetam is not extensively metabolized in humans.

The major metabolic pathway is the enzymatic hydrolysis of the acetamide group, which produces the carboxylic acid metabolite, ucb L057 (24% of dose) and is not dependent on any liver cytochrome P450 isoenzymes. The major metabolite is inactive in animal seizure models. Two minor metabolites were identified as the product of hydroxylation of the 2-oxo-pyrrolidine ring (2% of dose) and opening of the 2-oxo-pyrrolidine ring in position 5 (1% of dose).

There is no enantiomeric interconversion of levetiracetam or its major metabolite. Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration. Levetiracetam is eliminated from the systemic circulation by renal excretion as unchanged drug which represents 66% of administered dose.

The total body clearance is 0.96 mL/min/kg and the renal clearance is 0.6 mL/min/kg. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption. The metabolite ucb L057 is excreted by glomerular filtration and active tubular secretion with a renal clearance of 4 mL/min/kg. Levetiracetam elimination is correlated to creatinine clearance.

Levetiracetam clearance is reduced in patients with renal impairment [see Use in Specific Populations (8.6) and Dosage and Administration (2.5)]. Specific Populations Elderly Pharmacokinetics of levetiracetam were evaluated in 16 elderly subjects (age 61-88 years) with creatinine clearance ranging from 30 to 74 mL/min. Following oral administration of twice-daily dosing for 10 days, total body clearance decreased by 38% and the half-life was 2.5 hours longer in the elderly compared to healthy adults.

This is most likely due to the decrease in renal function in these subjects. Pediatric Patients Pharmacokinetics of levetiracetam were evaluated in 24 pediatric patients (age 6-12 years) after single dose (20 mg/kg). The body weight adjusted apparent clearance of levetiracetam was approximately 40% higher than in adults.

A repeat dose pharmacokinetic study was conducted in pediatric patients (age 4-12 years) at doses of 20 mg/kg/day, 40 mg/kg/day, and 60 mg/kg/day. The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.

The pharmacokinetics of levetiracetam in children was linear between 20 to 60 mg/kg/day. The potential interaction of levetiracetam with other AEDs was also evaluated in these patients. Levetiracetam had no significant effect on the plasma concentrations of carbamazepine, valproic acid, topiramate or lamotrigine. However, there was about a 22% increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing AED (e.g. carbamazepine).

Following single dose administration (20 mg/kg) of a 10% oral solution to children with epilepsy (1 month to < 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing. The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 mL/min/kg) than for adults (0.96 mL/min/kg).

Population pharmacokinetic analysis showed that body weight was significantly correlated to the clearance of levetiracetam in pediatric patients; clearance increased with an increase in body weight. Pediatric Patients with Obesity A population PK analysis of levetiracetam was conducted in 164 obese and non-obese pediatric patients 2 to <18 years of age with median (range) weight 39.2 (11.3-134) kg to evaluate the potential impact of obesity on plasma levetiracetam exposures.

Obesity was defined as BMI ≥95th percentile for age and sex based on CDC 2000 growth chart recommendations. Simulations were conducted for obese and non-obese pediatric patients ages 4 to <16 years. When the recommended tablet dose is administered to pediatric patients weighing < 40 kg, obese pediatric patients have 27% higher median C max,ss and 19% higher median C min,ss compared to non-obese patients.

When the recommended tablet dose is administered to pediatric patients weighing ≥ 40 kg, obese pediatric patients have 10-11% lower median C max,ss and 2% lower median C min,ss compared to non-obese patients. When the recommended oral solution dose is administered to pediatric patients across the full weight range, obese pediatric patients have 25% higher median C max,ss and 41% higher median C min,ss compared to non-obese pediatric patients.

However, differences in exposures between obese and non-obese pediatric patients are not expected to be clinically meaningful because the recommended dose titration at initiation of levetiracetam therapy would establish an appropriate dose for each individual patient. Pregnancy Levetiracetam levels may decrease during pregnancy [see Warnings and Precautions (5.11) and Use in Specific Populations (8.1)].

Gender Levetiracetam C max and AUC were 20% higher in women (N=11) compared to men (N=12). However, clearances adjusted for body weight were comparable. Race Formal pharmacokinetic studies of the effects of race have not been conducted. Cross-study comparisons involving Caucasians (N=12) and Asians (N=12), however, show that pharmacokinetics of levetiracetam were comparable between the two races.

Because levetiracetam is primarily renally excreted and there are no important racial differences in creatinine clearance, pharmacokinetic differences due to race are not expected. Renal Impairment The disposition of levetiracetam was studied in adult subjects with varying degrees of renal function. Total body clearance of levetiracetam is reduced in patients with impaired renal function by 40% in the mild group (CLcr = 50-80 mL/min), 50% in the moderate group (CLcr = 30-50 mL/min) and 60% in the severe renal impairment group (CLcr <30 mL/min).

Clearance of levetiracetam is correlated with creatinine clearance. In anuric (end stage renal disease) patients, the total body clearance decreased 70% compared to normal subjects (CLcr >80 mL/min). Approximately 50% of the pool of levetiracetam in the body is removed during a standard 4- hour hemodialysis procedure [see Dosage and Administration (2.5)].

Hepatic Impairment In subjects with mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment, the pharmacokinetics of levetiracetam were unchanged. In patients with severe hepatic impairment (Child-Pugh C), total body clearance was 50% that of normal subjects, but decreased renal clearance accounted for most of the decrease.

No dose adjustment is needed for patients with hepatic impairment. Drug Interactions In vitro data on metabolic interactions indicate that levetiracetam is unlikely to produce, or be subject to, pharmacokinetic interactions. Levetiracetam and its major metabolite, at concentrations well above C max levels achieved within the therapeutic dose range, are neither inhibitors of, nor high affinity substrates for, human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes.

In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid. Potential pharmacokinetic interactions of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.

Phenytoin KEPPRA (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy. Pharmacokinetics of levetiracetam were also not affected by phenytoin. Valproate KEPPRA (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers. Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion.

There also was no effect on exposure to and the excretion of the primary metabolite, ucb L057. Other Antiepileptic Drugs Potential drug interactions between KEPPRA and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.

These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam. Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.

Dose adjustment is not recommended. Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine. Oral Contraceptives KEPPRA (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.

Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam. Digoxin KEPPRA (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day. Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam.

Warfarin KEPPRA (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin. Prothrombin time was not affected by levetiracetam. Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam. Probenecid Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily.

C ss max of the metabolite, ucb L057, was approximately doubled in the presence of probenecid while the fraction of drug excreted unchanged in the urine remained the same. Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057.

The effect of KEPPRA on probenecid was not studied.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Levetiracetam 1 g Film coated tablet₱22.45–₱38.00Reference ₱22.45per tabletDPRI procurement range
Levetiracetam 100 mg/mL, 300 mL Bottle₱1,315.00–₱1,922.98Reference ₱1,315.00per bottleDPRI procurement range
Levetiracetam 250 mg Film coated tablet₱8.75–₱22.00Reference ₱11.76per tabletDPRI procurement range
Levetiracetam 500 mg Film coated tablet₱11.50–₱23.50Reference ₱16.38per tabletDPRI procurement range
Levetiracetam 500 mg/5 mL Vial₱1,200.00–₱2,348.00Reference ₱1,734.00per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Levetiracetam
PNF listingOral: 250 mg, 500 mg, 750 mg, and 1 g film coated tablet
PNF listingInj.: 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial
PNF listingSolution: 100 mg/mL oral solution, 100 mL and 300 mL bottle
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Keppra · UCB, Inc. [US FDA-approved label, version 36, January 28, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ca9df05-a506-4ec8-a4fe-320f1219ab21
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. UCB, Inc. (2026). KEPPRA (levetiracetam) tablets and oral solution [Prescribing information; US FDA-approved label, NDA021505, set ID 3ca9df05-a506-4ec8-a4fe-320f1219ab21, version effective January 28, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ca9df05-a506-4ec8-a4fe-320f1219ab21

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .